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CHAPTER 1: INTRODUCTION
Cigarette smoking is the chief cause of preventable death in the United States,
accounting for one out of five deaths annually (CDC, 2014). Although 70 percent of
smokers attempt to quit at least once in their lifetime, and 40 percent of smokers
attempt to quit yearly, most smokers relapse to smoking within days of a quit attempt
(CDC, 2014). People living with HIV/AIDS (PLWHA) are among a “special population” of
smokers, identified as those with greater smoking prevalence, disproportionate tobaccorelated health disparities, and less access to treatment relative to the general population
(Borelli, 2010). This high-risk group is also characterized by a deficit of populationspecific longitudinal treatment trials. PLWHA report significantly higher rates of cigarette
smoking, face increased negative physical health outcomes associated with smoking,
and experience more cessation treatment barriers than do those without HIV/AIDS
(Burkhalter, Springer, Chhabra, Ostroff, & Rapkin, 2005; Crothers et al., 2009). The
current study is part of the first randomized clinical trial of contingency management
(CM) for smoking cessation among PLWHA.
Cigarette Smoking and HIV/AIDS. Up to 70% of PLWHA report being daily
cigarette smokers (Burkhalter et al., 2005). Smokers who are HIV positive have
significantly increased mortality rates in addition to reduced CD4 cell counts, higher viral
load levels (i.e., HIV RNA), less responsiveness to antiretroviral treatment, and more
rapid progression to AIDS (Furber, Maheswaran, Newell, & Carroll, 2007). Relative to
non-infected smokers, HIV-positive smokers have increased rates of cancer,
respiratory, pulmonary, and bacterial illnesses, and lower life quality (Crothers et al.,
2009; Feldman et al., 2006). Importantly, quitting as well as increasing one’s duration of
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smoking abstinence significantly reduces HIV symptom burden (Vidrine, Arduino, &
Gritz, 2007).
There is a strong desire among PLWHA to quit smoking. One study showed that
63% of HIV-positive smokers want to stop smoking, and 72% have unsuccessfully
attempted to abstain from smoking (Mamary, Bahrs, & Martinez, 2002). Almost 70% of
these individuals expressed interest in a group intervention for smoking cessation, and
82% of these smokers were willing to participate in nicotine replacement therapy for
cessation. Despite this desire and motivation to discontinue tobacco use, there has
been a lack of consistent literature confirming the efficacy of varying cessation
treatments for HIV-positive individuals. Although pharmacological treatment trials
centered on nicotine replacement have sometimes demonstrated higher abstinence
rates relative to a no-treatment control (Elzi et al., 2006), others have shown low
medication adherence (Ingersoll, Cropsey, & Heckmann, 2009) or low rates of smoking
abstinence (Lloyd-Richardson et al., 2009). Behaviorally-based studies that aim to tailor
to PLWHA by addressing physical treatment barriers have demonstrated some shortterm cessation effects (e.g., Vidrine, Arduino, Lazev, & Gritz, 2006); however, more
longitudinal information is needed (Vidrine, Arduino, Lazev, & Gritz, 2012; Fjeldsoe,
Marshall, & Miller, 2009). There is a need to continue testing randomized longitudinal
treatment methods tailored to HIV-infected smokers. The larger randomized trial that
houses the current study is adapted to PLWHA not only through its use of bupropion as
a smoking cessation medication that does not interfere with antiretroviral treatment, but
also by its modification of ongoing treatment based on the individual responses of
participants, enhancing time and cost effectiveness.
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Cigarette Smoking and Violence Exposure. Two prominent types of violence
exposure commonly linked to psychological distress and functioning are community
violence and intimate partner violence. Violence is commonly defined as the use of
threatened or actual power or force against an individual or group that may result in
injury, death, psychological harm, abnormal development, or deprivation (Dahlberg &
Krug, 2002). Community violence exposure can be further characterized by witnessing
or personally experiencing stabbings, muggings, shootings, murders or other assaults
(Gorman-Smith, Henry, & Tolan, 2004). Intimate partner trauma refers to physical,
sexual, and psychological violence enacted by previous or current spouses and dating
partners, often occurring in the form of rape, physical assault, and stalking (CDC, 2011).
Although more women than men report partner violence exposure, almost 30% of men
report experiencing intimate partner violence in their lifetimes (Reid et al., 2008).
Interpersonal trauma exposure accounts for over 500,000 deaths annually and is
associated with significant physical, psychological, emotional, and financial burden
(CDC, 2003). Similarly, community violence exposure is consistently linked to mortality
in addition to social, psychological and physical affliction (World Health Organization
[WHO], 2002). Though violence exposure does not necessarily need to be recognized
by the victim as traumatic, individuals who undergo exposure in these forms often
experience posttraumatic stress symptoms or develop Posttraumatic Stress Disorder
(PTSD). Congruently, PTSD diagnoses require exposure to an event that involves
actual or threatened death or injury (American Psychiatric Association, 2013).
Substance use is one of the clearest correlates of these forms of violence
victimization (Beckham et al., 2005; Calhoun, Denis, & Beckham, 2007; Feldner et al.,
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2007; Koenen et al., 2005; Morissette et al. 2007), with 90% of adults with substance
use disorders reporting history of psychological trauma exposure (CDC, 2003). Studies
specifically show a strong relationship between violence exposure and increased rates
of smoking and nicotine dependence across genders and ethnicities (Buckley et al.,
2004; Dobie et al., 2004; Feldner et al., 2007; Hapke et al., 2005; Lassar et al., 2000).
These associations are observed independent of whether the smoker meets clinical
criteria for PTSD (Al Mamun et al., 2007; Hapke et al., 2005) and are sometimes
stronger than the correlation between prior trauma and alcohol consumption (Breslau et
al., 2003; Op Den Velde et al., 2002). Women who experience psychological (e.g.,
verbal) partner violence show increased risk of cigarette smoking, with even higher risk
of use when physical or sexual abuse enacted by intimate partners is reported (Jun et
al., 2008). Global studies additionally find that domestic violence is strongly associated
with tobacco use cross-culturally, particularly in areas where violence against women is
more prevalent (Ackerson, Kawachi, Barbeau, & Subramanian, 2007). Additionally, not
only does experiencing violence increase risk of initiating cigarette use, substance use
also reciprocally increases risk of being a victim or perpetrator of violence (Atkinson et
al., 2009; Krug et al., 2002). There is a strong need to examine the effects of different
modes of violence exposure on treatment outcomes and smoking abstinence.
There are a number of conceptual models that aim to explain linkages between
trauma and cigarette use. It is often suggested that nicotine is used to reduce the
emotional and sometimes physical discomfort associated with trauma (e.g., Logan et
al., 2002). Stress and coping models also explain smoking as a method of stress
reduction, associating stress with increased urges for cigarette smoking and cyclically
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less success in quitting smoking (Cohen & Lichtenstein, 1990; Jun, Rich-Edwards,
Boynton-Jarrett, & Wright, 2008). Severity of nicotine dependence has been positively
associated with avoidance, hyperarousal, and other PTSD symptoms (Thorndike,
Wernicke, Pearlman, & Haaga, 2006), suggesting that current tobacco use may be
related to peri-traumatic modes of tension reduction. Unsurprisingly, risk factors specific
to quitting smoking include anxiety, which is focal to post-traumatic stress.
Trauma exposure has also been implicated as a negative causal force on
smoking cessation treatment outcomes (Lasser et al., 2000), likely related to the
challenging cognitions and mood states that characteristically accompany trauma. This
post-trauma experience may include persistent negative beliefs (e.g., “no one can be
trusted”), distorted thought processes about the cause or outcomes of violence (e.g.,
self-blame), negative emotional states (e.g., fear, anger), difficulty experiencing positive
emotional states, and feelings of detachment from others (APA, 2013). Survivors of
violence are often challenged by building trust and finding purpose in life events, as well
as by feelings of guilt, shame, lack of power, and uncertainty (Feldner, Babson, &
Zvolensky, 2007). One study found that the severity of symptoms associated with
witnessing violent assaults and history of emotional abuse predicted poorer retention
and abstinence outcomes in a CM-based intervention for substance use (Ford et al.,
2007). Studies also show correlations between sexual trauma and treatment indicators
such as lack of trust, expression of feelings, and thought processing (Rosen et al.,
2002; Sikkema, 2007).
Violence Exposure and HIV/AIDS. Both intimate partner violence and
community violence exposure are common among individuals living with HIV/AIDS.
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Compared to 8.7% of the general population who report traumatic experiences, 62% of
HIV-positive individuals have experienced trauma exposure (Matchinger, Wilson,
Haberer, & Weiss, 2012). The experience of sexual abuse is strongly associated with
both HIV status and broader engagement in risky sexual behaviors (Sikkema et al.,
2007), with individuals who were abused being more likely to participate in high-risk
behaviors that increase exposure to HIV (e.g., Carballo-Dieguez & Dolezal, 1995).
Violence against women has also specifically been linked to sexually transmitted
infections including HIV infection (Gore-Felton, DiMarco, & Anderson, 2007). For
example, women who are in violent and abusive relationships are more likely to
experience abuse as a result of requesting the use of condoms, thus being less likely to
use sexual protection (Ajuwon et al., 2001; Kalichman et al. 1998; WHO, 2014;
Wingood & DiClemente, 1997).
Even among healthy individuals, violence exposure is associated with increased
engagement in risky behaviors, more somatic symptoms and fatigue, and poorer
immune and general health function (Baroso et al., 2010). The physiological effects of
violence exposure and post-trauma symptoms are even more highly related to health
outcomes among PLWHA. Physical and psychological stress associated with violent
experiences can contribute to hypothalamic-pituitary-adrenal (HPA) dysregularities that
negatively impact disease progression, HIV processes and presentation, and general
immunologic functioning (Biglino et al., 1995; Cole & Kemeny 1997). For example, HIV
positive individuals are more likely to have chronic cortisol elevations (i.e.,
hypercortisolemia), which may increase viral replication (Swanson et al., 1998).
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Violence is also linked to negative HIV-specific treatment outcomes. Interestingly,
one study found that trauma exposure was related to poorer treatment adherence in
black men as mediated by perceived discrimination (Wagner et al., 2012). The literature
additionally shows linkages among past violence exposure (e.g., combat, partner
abuse), development of PTSD from the HIV diagnosis itself, and post-diagnostic
psychiatric distress (Kelly et al., 1998), again highlighting a need to clinically attend to
previous trauma exposure. It has thus been suggested that HIV treatment incorporate
trauma and domestic violence screening as a mode of reducing symptoms that may
interfere with HIV treatment and health (Humphrey, 2014).
Protective Factors in the Treatment of Cigarette Smoking. Though protective
factors such as social support are related to smoking behaviors as well as health
outcomes for PLWHA, few studies have clearly examined the role of these buffers in
smoking treatment among this population. Further, no studies have examined
psychosocial protective and risk factors in a CM smoking cessation treatment design.
Social support, psychological distress, and life quality will be discussed here.
Social Support. Several studies show that social support not only increases
mobilization of psychological resources, but also provides tangible support such as
money, skills, and guidance (Bao, Whitbeck, & Hoyt, 2000; Cohen & Wills, 1985;
Maulik, Eaton, & Bradshaw, 2010). By the stress buffering model, social support
positively influences appraisals of threat following stressful events, bolstering perceived
ability to adequately cope with stressors. Alternatively, support can intervene after a
stress appraisal has been made, protecting against negative outcomes by increasing
positive reappraisals of the stressor, reducing perceived importance of the problem, or
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providing solutions to the problem (Cohen et al., 1985). Importantly, lack of social
support is associated with elevated smoking rates and reduced cessation (May & West,
2000), and has been shown to be related to maladaptive, avoidant coping strategies
among HIV-positive men (Leserman et al., 1992; Tate et al., 2006). Social support has
congruently been found to be effective in smoking cessation treatment in the general
nicotine-dependent population (Fiore et al., 2008). Perceived social support is also
related to experiences of violence victimization, often buffering against negative effects
of traumatic events among adults (Nordentoft, 2010).
There remains a need to research the effects of social support on health and
substance cessation among PLWHA. The limited literature on social support as a
protective factor in the mental and physical health of HIV-positive adults is mixed
(Ironson & Hayward, 2008). Some studies show a positive effect of social support on
physical and mental health (Ashton et al., 2005; Leserman et al., 2002), while others
find weak associations (e.g., Ironson et al., 2005), or suggest that support is only
predictive of better health when individuals are in advanced stages of disease infection
(Patterson et al., 1996).
It is possible that there are social components specific to HIV/AIDS that separate
the disease from other chronic medical illnesses (e.g., cancer, cardiovascular disease)
for which social support is consistently linked to increased health. One study found that
PLWHA who report increased social support also report more engagement in risky
sexual behaviors (Holmes & Pace, 2002; Miller & Cole, 1998). It is also likely that
certain groups more prevalently sampled in earlier studies (e.g., HIV-positive men who
sleep with men) are operationally different than other HIV-positive subgroups in social
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and social support characteristics. Additionally, social support for PLWHA may differ as
a product of the social stigma associated with HIV status (Gostin & Webber, 1998;
Vanable et al. 2006). In light of the social and medical complexity of HIV/AIDS, it is
important to continue investigating the multifaceted impact of social support on PLWHA.
Psychological Distress and Life Quality. Depression is associated with more than
twice the risk of HIV progression to AIDS (Golub et al., 2003). Examining change in
depressive symptoms longitudinally, the Coping in Health and Illness Project found that
for every cumulative increase in depressive symptoms, AIDS risk doubled at 5.5 years
(Leserman et al., 2008, 2002, 1999). Another study among women showed that
depression measured longitudinally was associated with 61% increased risk of clinical
progression and more than double the risk of fatality (Antelman et al., 2007). Distress
specifically related to trauma is also instrumental in the medical health of HIV-positive
individuals, with post-violence avoidance and intrusion being linked to more depression
and lower CD4+ percentages (Lutgendorf et al., 1997). Depression is also heavily linked
to nicotine dependence, withdrawal, and ability to quit smoking in the general population
(Glassman et al., 2001; O’Brien et al., 2004). As rates of current depression are three
times higher in HIV-positive individuals than in the general population (Ferrando &
Freyberg, 2008; Reynolds, 2009), there is a critical need to address the role of
depression in substance treatment for PLWHA.
Stressful life events are also strongly related to rapid HIV disease progression.
One early study found that for each stressful life event in a six-month period, the risk of
early HIV disease progression doubled (Evans et al., 1997). Meta-analyses have shown
that, along with distress and prior trauma, stressful events negatively impact HIV
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disease progression, acting to lower CD4 T lymphocytes, and increase viral load,
clinical decline, and mortality (Leserman, 2008). Life quality is also often linked to
cigarette smoking, with increased smoking being related to lower life quality, and
abstinence promoting higher life quality (Hays, Croghan, Baker, Cappelleri, &
Bushmakin, 2012). Both depression and life quality negatively impact smoking
cessation treatment in the general population (Cinciripini et al., 2003; Freedland et al.,
2005), though it is unclear the specific effect it has on smokers living with HIV/AIDS,
who report significantly higher rates of psychiatric illness.
Contingency Management. Among a growing number of interventions focused
on reducing smoking behaviors, contingency management (CM) has demonstrated
efficacy in improving substance cessation outcomes across several patient populations
(e.g., Alessi et al., 2004; Dutra et al., 2008; Ledgerwood et al., 2008; Petry & Alessi,
2010). CM is founded on the concept that voluntary behavior exists in the context of
environmental contingencies, wherein frequency of behavior occurs in correlation with
the desire to obtain or avoid positive or negative consequences (Skinner, 1953).
By this theoretical approach, cigarette smoking is reinforced and maintained via
an operant conditioning process involving the biochemical effects of nicotine as well as
environmental reinforcers (e.g., increased social interaction; Higgins & Petry, 1999).
Providers select a target behavior that indicates smoking abstinence (e.g., low cotinine
levels), and offer incentives which are likely to be rewarding to the smoker. Through this
process, behavioral principles of reinforcement operate to counteract the reinforcing
mechanisms of chronic smoking. CM has previously been used to reduce HIV-related
risk behaviors, such as antiretroviral medication adherence (Haug & Sorensen, 2006).
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The present study uses prize-based CM, which was developed as an alternative
to more costly monetary and voucher CM treatment systems (Petry et al., 2000). Rather
than offering money or vouchers, which typically exceed maximum reinforcement
amounts of 1,000 dollars (Higgins et al., 2004; Silverman et al., 1998), prize-based CM
offers the opportunity to win prizes of varying magnitudes at a particular reinforcement
schedule. Prize-based CM is an efficacious approach to the treatment of a range of
substances (Petry et al., 2005; Pierce et al., 2006) including nicotine (Ledgerwood et al.,
2014). The larger clinical trial that houses the present study is the first to assess the
effects of prize-based CM among PLWHA.
Current Study
The present study examined how risk and protective factors impact cessation
efforts among PLWHA undergoing contingency-based treatment for cigarette smoking.
Specifically, this study aimed to assess (1) how community and interpersonal partner
violence exposure affect smoking cessation among PLWHA, (2) how high depression
and low life satisfaction affect smoking cessation among PLWHA, (3) how social
support affects smoking cessation among PLWHA, and (4) whether social support
moderates relationships between predictors and smoking cessation success among
PLWHA.
Smoking Cessation. Smoking cessation success was measured by six smoking
indicators: (1) urinary cotinine, (2) longest duration of continuous abstinence, (3) selfreported cigarette use, (4) self-reported change in withdrawal symptoms, (5) selfreported change in smoking urges, and (6) self-reported change in motivations for
quitting smoking. To better understand change in smoking cessation from pre to post-
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treatment, change scores (X-Y) were assessed from intake (X) to post-Phase 1 (Y) and
2 (Z). Smoking cessation scores assessed following the first and second treatment
phases were used for the current analyses. These cessation indicators are described in
more detail in Chapter 2 (Method).
Community and Partner Violence Exposure. Self-reported violence exposure
scores reported at the intake assessment were used to predict cigarette use outcomes
measured after the first and second phases of treatment. I hypothesized that both
increased community violence and intimate partner violence exposure would be
inversely related to smoking cessation indicators. Specifically, increased violence
exposure will predict lower levels of abstinence, fewer days of continuous abstinence,
greater cigarette use, greater withdrawal symptoms, more urges to smoke, and fewer
reasons for quitting smoking.
High Depression and Low Life Satisfaction. Depression and life satisfaction
assessed during the intake session were used to predict post-Phase 1 and post-Phase
2 smoking outcomes. I hypothesized that higher depression and lower life satisfaction
would be inversely related to smoking cessation indicators. Specifically, high depression
and low quality of life will predict lower levels of abstinence, fewer continuous days of
abstinence, greater use frequency, greater withdrawal symptoms, more urges to smoke,
and fewer reasons for quitting smoking.
Social Support. Social support assesses appraisal, belonging, available help,
and self-esteem support. A moderation model examined the effect of perceived social
support, as self-reported in the intake assessment, on the relationship between the
above

noted

predictor

variables

(community

violence,

interpersonal

violence,
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depression, and life satisfaction), and the above noted outcome variables (changes in
cotinine, changes in use frequency, changes in withdrawal, changes in urges, changes
in motivations for quitting smoking, and LDA). I hypothesized that social support would
be positively related to smoking cessation indicators. Additionally, increased social
support will moderate the relationship between increased violence exposure and
smoking, higher depression and smoking, and lower life satisfaction and smoking, such
that increased social support will be related to reduced smoking indicators.
Treatment Condition. Treatment condition assignment in Phase 1 of the study
was additionally assessed and controlled for. Treatment condition was randomly
assigned. Phase 1 treatments are described in detail at a later point.
Thus, this study used longitudinal data and hierarchical regressions to test four
hypotheses: (1) increased violence exposure is related to poorer smoking cessation
outcomes, (2) higher depression and lower life satisfaction is related to poorer smoking
cessation outcomes, (3) social support is positively related to smoking cessation
outcomes, and (4) social support moderates the relationship between violence history
and smoking, depression and smoking, and life satisfaction and smoking.
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CHAPTER 2: METHOD
Participants
Participants are those who are enrolled in a larger randomized clinical trial of
contingency management for smoking cessation among PLWHA (NIH grant R01
DA034537-01A1; clinical trial identifier: NCT01965405). Participants are 40 daily
cigarette smokers from the Wayne State University Physician’s Group (WSUPG) adult
HIV/AIDS clinic located in Detroit. These individuals represent a portion of the
participants in the larger clinical trial study. The number of participants included in the
current study was dependent on the rate of participant recruitment and eligibility.
Inclusion criteria are as follows: at least 18 years of age, ability to read and understand
English, use of at least 10 cigarettes daily, and patient attendance at the WSUPG
HIV/AIDS clinic. Exclusion criteria are as follows: active suicidality, uncontrolled manic
or psychotic symptoms, being in recovery for pathological gambling, having
contraindications for bupropion treatment (e.g., epilepsy, use of MAO inhibitors/other
antidepressants, presence of eating disorders/low body mass), or participation in other
smoking cessation interventions.
A sequential Multiple Assignment Randomized Trial (SMART) design is used in
the larger study. SMART utilizes a stepped-care method that tailors treatment to initial
treatment response. Participants in Phase 1 who respond to initial brief treatment (i.e.,
reduce their smoking) received a different treatment assignment in Phase 2 than
participants in Phase 1 who do not respond to initial treatment (i.e., do not reduce their
smoking).
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Participants in Phase 1 were randomized to one of two brief interventions: (1)
counseling care and bupropion pharmacotherapy (i.e., standard of care), or (2)
Standard of care in addition to high magnitude prize contingency management (CM).
Treatments are described in more detail below. Upon completion of Phase 1,
participants were classified as Responders or Non-Responders based on their smoking
reduction or abstinence.
Non-responders who enter Phase 2a were randomly assigned to one of two
conditions: (1) continued counseling and monitoring support, or (2) monitoring support
and prize CM. Phase 1 responders who enter Phase 2b were randomly assigned to one
of two conditions: (1) no additional treatment, or (2) continued monitoring and low
intensity prize CM. Treatments are described in more detail below.
Random assignment to treatment conditions was balanced by gender, and
average daily number of cigarettes smoked (< 1 pack/day, or > 1 pack/day). An urn
randomization procedure was used to equate groups across these parameters. Random
assignment to Phase 1 treatment conditions occurred during the initial intake (day 1 of
treatment), and random assignment to Phase 2a and 2b treatment conditions occurred
at the start of Phase 2, balanced in the same way as Phase 1. The present study was
conducted in accordance with Declaration of Helsinki and was approved by the Wayne
State University Institutional Review Board.
The study’s stepped care design addresses criticisms of a CM-based approach
to cessation treatment in that it aimed to be less time-intensive and more cost-effective.
The design minimized time requirements and prize-based treatment for individuals who
responded to brief treatment and do not require continuing CM, implementing a more
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intensive CM schedule only for those with matching clinical need. The study additionally
used prize-based CM in place of more costly cash or voucher-based alternatives
(Higgins et al. 2004), reducing costs by rewarding opportunities to earn prizes of varying
magnitude rather than using money or money-based vouchers (Petry et al., 2000,
2005).
Treatments
The larger clinical trial involves two treatment phases (4 weeks, and 8 weeks
long respectively), followed by 6 and 12-month post-treatment follow-ups. The present
study used data from the baseline assessment, the post-Phase 1 (weeks 1-4) treatment
assessment, and the post-Phase 2 (weeks 5-12) treatment assessment.
Phase 1. Phase 1 spanned four weeks, and included participant randomization
into either Standard of Care, or Standard of Care plus High-Magnitude Prize
Contingency Management.
Standard of Care. Standard care involved (1) monitoring of smoking cessation
using biological indicators (urinary cotinine) and medication compliance, (2) brief
counseling based on clinical practice guidelines (Fiore et al., 2008), and (3) bupropion
pharmacotherapy. Participants met with the research therapist weekly for four weeks to
provide samples and receive 15-minute counseling geared toward smoking cessation.
Counseling was based on the 5As/Rs model.
The 5As/Rs approach involved the 5 As: (1) Ask about tobacco use, (2) Advise
the participant to quit smoking, (3) Assess willingness to quit, (4) Assist in the quit
attempt through supportive counseling, and (5) Arrange follow-up assessments (U.S.
Public Health Service [USPHS]). The 5 Rs were used to address ambivalence about
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quitting smoking, and are based on motivational interviewing principles. The 5 Rs are:
(1) encourage the participant to indicate personal Relevance of quitting smoking, (2)
have the participant identify Risks of continued tobacco use, (3) together identify
potential Rewards of quitting smoking, (4) identify Roadblocks or barriers to quitting,
and show how counseling may address these barriers, and (5) Repeat motivational
interviewing at each subsequent visit. The therapist also reviewed a smoking cessation
self-help quit guide with the participant titled You Can Quit Smoking, which emphasizes
the importance of motivation, social support, and behavioral skills in reducing smoking
behaviors (U.S. Department of Health and Human Services). Specifically, the guide
addresses reasons for quitting smoking, preparing to quit, gaining social support
specific to cessation, skills building, use of medications, and relapse prevention and
preparation.
All participants, regardless of condition, were prescribed sustained release
bupropion, which has demonstrated efficacy in smoking cessation (Hughes, Stead,
Hartmann-Boyce, Cahill, & Lancaster, 2014), is in-line with current Standard of Care,
and does not interfere with assessment of urinary cotinine levels. Participants received
a flexible dosing procedure of 150 mg/day for the first three days followed by a potential
dose increase to 300 mg/day depending on medication tolerability. The recommended
maximum dose of bupropion for smoking is 300 mg/day, or 150 mg twice/day at 8-hour
intervals (Aubin, 2002). The study physician prescribed bupropion and adjusted
dosages based on clinical observation and monitoring of participant responses using
the Bupropion Adverse Effects Checklist. Bupropion treatment continued for 12 weeks
(Phase 1, and Phase 2a/b) with a two-week taper to 150 mg in week 11, 75 mg in week
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12, and 0 mg at the end of week 12. Studies show that bupropion is efficacious and safe
for treating PLWHA and those taking antiretroviral medications (Currier, Molina, & Kato,
2003; Pedrol-Clotet et al., 2006). Bupropion administration compliance was closely
monitored to assess differential impact on treatment outcomes among treatment
conditions. Research assistants conducted pill counts and reviewed participant selfreports of medication compliance.
Standard of Care Plus High Magnitude Prize Contingency Management.
Participants in the High Magnitude condition received the same cotinine test result
monitoring and brief counseling procedures described above (see Standard of Care
section, p. 16), and provided CO and cotinine samples on the same schedule.
Participants additionally earned chances to win prizes if they met criteria for early
smoking reduction or abstinence (Petry, 2000; Petry et al., 2004). Criteria included
cotinine levels lower than the most recent level provided, or below the abstinence cut off
of < 2. If the participant reduced their cotinine score, but then lapsed, the participant had
to reduce subsequent cotinine levels from the point of the lapse to regain a chance for
reinforcement. Presenting with a cotinine level above the cutoff, refusing to provide a
sample, or being absent without excuse (e.g., illness, family emergency) resulted in
draws being reset to one draw for the next provided negative sample. Participants
earned draws from the prize-bowl during each weekly session in which they met the
reduction/abstinence criteria. In each of weeks 2-4 of treatment, when participants
reduce scores from the previous week, they earn one additional draw. That is, reducing
smoking at the week 2 session earns the participant two draws; reducing smoking at
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week 3 earns the participant three draws, et cetera. By the end of the fourth treatment
week, participants may earn up to a total of 10 draws.
The prize urn for Phase 1 of treatment included 50 slips of paper with the
following breakdown: 60% (30 slips) result in a large prize ($20); 30% (15 slips) result in
a super prize ($50); 10% (5) result in a jumbo prize ($100). Participants may earn an
average maximum of $370 in reinforcement if they abstain from smoking throughout this
phase.
Phase 2. Phase 2a assigned treatment non-responders from Phase 1 to one of
two conditions: (1) continued counseling and monitoring, or (2) continued counseling
plus 8-week prize CM. Phase 2b assigned treatment responders from Phase 1 to one of
two conditions: (1) no additional intervention, consistent with standard of care, or (2)
continued counseling and monitoring, and 8-week low-magnitude prize CM. Phase 2a
and 2b treatments are described in more detail below.
Treatment non-responders were classified as those who continued to smoke at
levels similar to baseline at the conclusion of Phase 1, determined by objective
indicators of smoking: (1) urinary cotinine levels that are not reduced from baseline (i.e.,
< 2 points pre to post change), or (2) expired CO levels that are not significantly
reduced (i.e., > 3 ppm on the final day of testing). Treatment responders were classified
as those who significantly reduced smoking as defined by cotinine levels substantially
lower than baseline scores (> 2 point reduction), or abstinence based on expired CO at
the final visit (< 3 ppm). The cut-off of < 3 ppm has demonstrated high sensitivity and
specificity for abstinence (e.g., Javors, Hatch, & Lamb, 2004). As cotinine has a longer
half-life relative to that of CO (20 hours versus four hours for CO; Benowitz & Jacob,
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1997), a reduction score of > 2 points was chosen as an indicator of recent treatment
responsiveness.
Phase 2a. All non-responders continued to receive medical monitoring of
bupropion for 8 additional treatment weeks, in addition to the randomly assigned
treatment.
Counseling and Monitoring of Smoking (MS). Participants met with the study
therapists twice weekly to review smoking cessation progress, provide breath samples
for CO testing, and provide urine samples for weekly cotinine testing. Therapists
provided support and encouragement as well as results of weekly testing.
MS Plus Contingency Management (MS+CM). Participants received the
treatment as MS treatment participants, in addition to prize CM for abstinence, weekly
for 8 weeks. The method for prize drawing was similar to that of Phase 1; thus,
participants received prize draws during weekly therapist meetings if cotinine levels
were lower than the most recent level previously provided, or levels were below or at
the absolute cutoff of 2. Participants received one draw on the first day of treatment,
with escalating draws at each consecutive, negative cotinine test up to a total of 10
draws on a given day. Once the participant earned the maximum number of draws, the
participant received that number of draws at each subsequent negative cotinine
reading. The same reset contingencies as described in Phase 1 were used; however,
resets were reversed once the participant reached three consecutive, negative samples
(i.e., the number of prizes will be restored to the highest achieved level pre-reset).
Additionally, every third consecutive test that met reinforcement criteria earned the
participant five bonus draws. Phase 2 reset contingencies are dissimilar to the Phase 1

21
reset protocol solely because there were not enough testing sessions in Phase 1 to
restore resets.
The prize urn for Phase 2 of treatment included 500 slips of paper with the
following breakdown: 50% (250 slips) result in no prize (e.g., “Good job!”); 42.6% (213
slips) result in a small prize ($2); 7% (35 slips) result in a large prize ($20); .4% (2 slips)
result in a jumbo prize ($100). Participants may earn up to 115 draws plus 25 bonus
draws over the eight-week treatment period, with an average maximum value of $371 in
prize reinforcement.
Phase 2b. Similar to Phase 2a (non-responder) treatments, all responders
continued to receive medical monitoring of bupropion treatment for 8 treatment weeks,
in addition to randomly assigned Phase 2 conditions.
No Additional Treatment (NAT). Participants received no additional treatment of
smoking monitoring following Phase 1, consistent with SoC methods that followed brief
treatment and medication administration. NAT participants were contacted for follow-up
assessments only.
Counseling and Monitoring of Smoking Plus Low Intensity Prize CM. Participants
received the same counseling and monitoring as described in 2a treatments, with less
frequency. Participants met with research therapists weekly for four weeks, and
biweekly for four weeks (i.e., 6 total meetings), to provide cotinine and CO samples.
Participants received prize draws during therapy meetings if their cotinine levels were
less than either the most recent level, or level 2. Participants used the same prize urn
specified in the MS+CM condition, but began with 5 draws, which escalated to a
maximum of 10 draws for subsequent negative cotinine tests. Reset contingencies were
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in-place for positive tests or missed sessions. The prize urn was similar to that
described above for Phase 2a and participants had the opportunity to earn up to 45
draws plus 5 bonus draws over the 8-week treatment period, with an average maximum
dollar value of $133 in prizes.
Measures
Demographics

and

Inclusion/Exclusion.

Gender,

age,

marital

status,

education and annual income were collected at intake. To assess exclusion criteria, a
brief screen of suicidality, psychosis, and substance use symptoms were used, adapted
using scales from the Structured Clinical Interview for the DSM-IV-TR (First, Spitzer,
Gibbon, & Williams, 2002).
Smoking History. At the time of the intake interview, participants were asked
about age of first smoking, age of first daily smoking, current number of cigarettes
typically smoked daily, past quit attempts, and periods of abstinence. The Fagerström
questionnaire was a brief measure of physical dependence to nicotine (Fagerström,
1978; Heatherton et al., 1991) and was used as a measure of nicotine dependence.
Things I Have Seen and Heard (TSH). A modified version of the TSH (Richters
& Martinez, 1990) was used to assess exposure to community violence. The TSH
includes 20 items that assessed exposure to neighborhood violence, specifically
measuring witnessing or being victimized by violence in the community. Respondents
self-reported their lifetime exposure to specific violent events on a 5-point scale ranging
from “never” to “always.” The TSH demonstrates good psychometric properties,
including internal consistency (Cronbach’s alpha = .76-.80; Richters & Martinez). The
TSH was administered at intake.
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Revised Conflict Tactics Scale—Short Form (CTS2S). The CTS2S is a brief
form of the Revised Conflict Tactics Scale (Straus & Douglas, 2004). It includes 20
items that measure exposure to interpersonal violence among intimate partners,
assessing psychological and physical attacks experienced and perpetrated in the past
year. The CTS2S demonstrates good internal consistency, test-retest reliability, and
validity (Straus, Hamby, Boney-McCoy, & Sugarman, 1996). The CTS2S was
administered at intake.
Beck Depression Inventory, Second Edition (BDI-II). The Beck Depression
Inventory, Second Edition (BDI-II) is a 21-item self-report measure of past 14-day
depression symptoms (Beck, Steer, & Garbin, 1988). Scores range from 0-63, with
scores of 0-13 categorized as Minimal Depression, scores of 14-19 categorized as Mild
Depression, scores of 20-28 categorized as Moderate Depression, and scores of 29-63
categorized as Severe Depression. The BDI-II is a widely used, valid, and reliable
measure of recent depression symptoms. The BDI-II was administered at intake.
Quality of Life Inventory (QOL). The QOL assesses satisfaction in 17 life
areas, including work, health, recreation, and goals (Frisch, 1994). This measure was
used to assess life satisfaction. The QOL has test-retest coefficients ranging from .80.91 and correlates with other measures of well-being (Frisch et al., 2005). The QOL was
administered at intake.
Interpersonal Support Evaluation List (ISEL). The ISEL (Cohen & Hoberman,
1983) is a 40-item scale that provides an index of overall perceived social support. The
ISEL assesses appraisals, belongingness, available help, and self-esteem support.
Response options range from definitely false (1) to definitely true (4), with high scores
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indicating greater overall social support. The ISEL total score demonstrates good
reliability in a variety of samples (Cronbach’s alpha = .88-.90; Cohen & Hoberman,
1983). The ISEL was administered at intake.
Cotinine. Cotinine is nicotine metabolite and a sensitive measure of smoking
that was assessed by urinalysis using the Accutest NicAlert test-strip system (JANT
Pharmacal Corporation). Through this test-strip system, cotinine was reported semiquantitatively, with ordinal scores of 0 through 6 being assigned based on cotinine
concentrations (ng/mL). Level 0 indicates 1-10 ng/mL; level 1 indicates 11-30 ng/mL;
level 2 indicates 31-100 ng/mL; level 3 indicates 101-200 ng/mL; level 4 indicates 201500 ng/mL; level 5 indicates 501-1000 ng/mL; level 6 indicates > 1000 ng/mL. Cotinine
levels less than or equivalent to 100 ng/mL, or < level 2, were considered negative for
cigarette smoking (Benowitz, Hukkanen, & Jacob, 2009).
Due to the variance within each ordinally assigned level and the subsequent
inability to analyze precise cotinine concentrations, a change score (X-Y) was used to
assess whether cotinine level was reduced from intake (X) to post-treatment (Y). This
was done to better detect change in smoking abstinence. Use of change scores as
dependent variables is effectively used in regression analyses (Allison, 1990). Change
scores may be limited by the fact that they are associated with both baseline and timepoint (post-Phase 1 and 2) scores. However, use of change scores in this study
preserves power of analyses relative to alternative methods of change measurement
(e.g., predicting raw time-point scores while additionally controlling for baseline scores)
by reducing the number of variables analyzed. Though cotinine was assessed at
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various time points, cotinine levels assessed following the first and second treatment
phases were used for the current analyses.
Timeline Follow-back – Cigarette (TLFB-C). The TLFB-C is a self-report,
calendar-based measure of the quantity and frequency of cigarette smoking (Sobell et
al., 1979). Average number of cigarettes smoked in the past month (30 days) was used
to assess cigarette use. This particular measure of cigarette use with the TLFB-C is
valid and reliable (Brown et al., 1998; Robinson, Sobell, Sobell, & Leo, 2012). To better
understand change in cigarette use from pre to post-treatment, a change score (X-Y)
was assessed from intake (X) to post-Phase 1 (Y) and 2 (Z) (Allison, 1990). Though the
TLFB-C will be administered at various time points, TLFB-C scores assessed following
completion of the first and second treatment phases were used for the current analyses.
Longest Duration of Continuous Abstinence (LDA). Duration of continuous
abstinence from smoking was measured in days, and is defined as the number of the
longest string of consecutive days of smoking abstinence (Ledgerwood, Arfken, Petry, &
Alessi, 2014). LDA was constructed using the TLFB-C in conjunction with (i.e.,
confirmed by) reported cotinine levels, and used data from intake to the conclusion of
treatment (post-Phase 2). LDA is a robust predictor of future abstinence (Ferguson et
al., 2003; Petry, Alessi, & Ledgerwood, 2012).
Minnesota Nicotine Withdrawal Scale (MNWS). The MNWS is a 15-item selfreport of nicotine withdrawal symptoms such as anxiety, hunger, and irritability
(Cappelleri et al., 2005; Hughes & Hatsukami, 1986). Each symptom is rated on a 5point scale ranging from “no” to “severe” withdrawal symptoms. To better understand
change in withdrawal from pre to post-treatment, a change score (X-Y) was assessed
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from intake (X) to post-Phase 1 (Y) and 2 (Z) (Allison, 1990). Though the MNWS was
administered at various time points, MNWS scores assessed following the first and
second treatment phases were used for the current analyses.
Questionnaire of Smoking Urges (QSU-Brief). The brief form of the QSU is a
10-item self-report measure that assesses craving to smoke, including anticipated
positive effects of smoking, and intention to smoke (Davies, Willner, & Morgan, 2000;
Willner, Hardman, & Eaton, 1995; Tiffany & Drobes, 1991). To better understand
change in urges from pre to post-treatment, a change score (X-Y) was assessed from
intake (X) to post-Phase 1 (Y) and 2 (Z) (Allison, 1990). Though the QSU was
administered at various time points, QSU scores assessed following the first and
second treatment phases was used for the current analyses.
Reasons for Quitting (RFQ). The RFQ is a 20-item self-report measure of
motivation to quit smoking (Curry et al., 1991). This measure includes four scales, with
two reflecting intrinsic motivation (health concerns and desire for self-control), and two
reflecting extrinsic motivation (immediate reinforcement and social influence). The
present study uses the RFQ total score in order to understand overall motivation to quit
smoking. This scale has been validated in studies of smokers (Curry, et al., 1991). To
better understand change in motivation to quit smoking from pre to post-treatment, a
change score (X-Y) was assessed from intake (X) to post-Phase 1 (Y) and 2 (Z)
(Allison, 1990). Though the RFQ was administered at various time points, RFQ scores
assessed following completion of the first and second treatment phases were used for
the current analyses.
Analysis of Aims
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Four hypotheses were tested using hierarchical multiple regressions. (1) The
relationship between increased violence exposure (community violence, intimate
partner violence) and smoking cessation outcomes (change in cotinine scores, cigarette
use, withdrawal, urges, motivations for quitting smoking, and LDA for the total treatment
period) was tested while controlling for differences explained by sociodemographic and
initial treatment condition variables (age, gender, education, nicotine dependence, initial
treatment condition assignment). This regression included community violence and
intimate partner violence scores as predictor variables in the first hierarchical regression
block, and sociodemographic and treatment variables in the second regression block.
Primary study variables were entered in the first blocks to gain a better understanding of
both the model fit of the primary study variables, and the model fit of the primary
variables while secondarily controlling for sociodemographic variables and initial
treatment condition (e.g., Newman & Thompson, 2003). Outcome variables measured
at the completion of Phase 1 (Post-Phase 1 change in cotinine, cigarette use,
withdrawal, urges, motivations for quitting smoking) and outcome variables measured at
the completion of Phase 2 (Post-Phase 2 change in cotinine, cigarette use, withdrawal,
urges, motivations for quitting smoking, and LDA) were assessed in separate regression
sets.
(2) The relationship between higher depressive symptoms scores and lower life
satisfaction scores and smoking cessation outcomes (change in cotinine scores,
cigarette use, withdrawal, urges, motivations for quitting smoking, and LDA for the total
treatment period) was tested while controlling for differences explained by
sociodemographic and initial treatment condition variables (age, gender, education,
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nicotine dependence, initial treatment condition assignment). This regression included
depressive symptoms and life satisfaction scores as predictor variables in the first
hierarchical regression block, and sociodemographic and treatment variables in the
second regression block (Newman & Thompson, 2003). Outcome variables measured
at the completion of Phase 1 (Post-Phase 1 change in cotinine, cigarette use,
withdrawal, urges, motivations for quitting smoking) and outcome variables measured at
the completion of Phase 2 (Post-Phase 2 change in cotinine, cigarette use, withdrawal,
urges, motivations for quitting smoking, and LDA) were assessed in separate regression
sets.
(3) The relationship between social support and smoking cessation outcomes
(change in cotinine scores, cigarette use, withdrawal, urges, motivations for quitting
smoking, and LDA for the total treatment period) and (4) the moderation of social
support on the relationships between violence exposure and smoking, depressive
symptoms and life satisfaction and smoking was tested while controlling for differences
explained by sociodemographic and initial treatment condition variables (age, gender,
education, nicotine dependence, initial treatment condition assignment). Regressions
included social support and primary predictor variables (community violence and
intimate partner violence exposure; depressive symptoms and life satisfaction scores) in
the first blocks, and sociodemographic and treatment variables in the second blocks
(Newman & Thompson, 2003). Third blocks included two-way interaction terms between
social support and predictor variables (social support by exposure to community
violence, and social support by intimate partner violence; social support by depressive
symptoms scores, and social support by life satisfaction scores). Regressions were run
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separately for each primary predictor variable to reduce collinearity and increase the
power of analyses. Outcome variables measured at the completion of Phase 1 (PostPhase 1 change in cotinine, cigarette use, withdrawal, urges, motivations for quitting
smoking) and outcome variables measured at the completion of Phase 2 (Post-Phase 2
change in cotinine, cigarette use, withdrawal, urges, motivations for quitting smoking,
and LDA) were assessed in separate regression sets.
Analyses did not involve correction procedures for the study’s 22 multiple
regressions and 24 moderation regressions. This decision was made because the
consequent reduction in Type I statistical error (i.e., false discoveries) would
subsequently increase the probability of Type II statistical error (i.e., false rejections),
particularly with the modest sample size of the current study (Gelman, Hill, & Yajima,
2012).
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CHAPTER 3: RESULTS
Preliminary Analyses
Statistical Package for the Social Sciences (SPSS) Version 22 was used for all
analyses. Adequate power existed for all analyses given these statistical tests and the
present study’s sample size. This determination was based on literature which reports a
standard of five observations needed per independent variable in multiple linear
regression to maintain adequate power (Bartlett, Kotrlik, & Higgins, 2001; Hair,
Anderson, Tatham, & Black, 1995). In addition, a power analysis was conducted using
Gpower 3.1.9.2 statistical analysis software (Faul, Erdfelder, Lang, & Buchner, 2007).
This power analysis of the current study parameters reported a power statistic of .81 at
a .05 significance criterion, indicating adequate statistical power for the current analyses
(Cohen, 1998; Ellis, 2010).
Data were screened for accuracy of input, univariate and multivariate outliers,
and amount and distribution of missing data (see Table 1 for full descriptive statistics).
No univariate or multivariate outliers were detected. Six participants failed to complete
the intended 12-week treatment. Missing data for these 6 participants were identified as
data not-missing-at-random. Missing data for these participants were imputed by
method of last observation carried forward (LOCF). LOCF is a frequently used,
conservative (i.e., underestimates, rather than falsely overestimates, true treatment
effects) method of data imputation in longitudinal studies (Gelman & Hill, 2006),
particularly when data are missing not-at-random (Higgins & Green, 2011). LOCF
additionally avoids distorting both the distribution of data, and multivariate relationships,
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as commonly occurs when missing data are replaced with the mean of observed values
(i.e., mean imputation; Gelman & Hill).
Normality and linearity among variables were examined using skew and kurtosis
statistics, histograms of standardized residuals, and P-Plots of regression standardized
residuals. Calculations of skew and kurtosis identified skew among the outcome
variables of Post-Phase 1 and Post-Phase 2 cotinine change scores, and LDA (using a
skew and kurtosis cut-off level of +1.96). Variables were transformed for normality using
square root and log transformations; however, variables remained above the cut-off
level indicating skew and kurtosis. Skew of these variables was interpreted as related to
the smoking severity of the current sample, particularly with use of the ordinal-level,
range-restricted variable of cotinine. Residual plots of standardized residuals appeared
linear and homogenous, and thus indicated appropriate fit of study variables to
parametric analyses (Stevens, 2009). Research further indicates that multiple
regression analysis is robust to assumptions of normality (Frost, 2014; Gelman & Hill,
2007; van Belle, 2008). Variables were additionally screened for multicollinearity and
singularity by examination of bivariate correlations, variance inflation factors (VIF), and
tolerance statistics. There was no evidence of multicollinearity or singularity. Bivariate
correlations were calculated for all study variables (see Table 2).
Sociodemographic Variables. Descriptive statistics for all study variables are
presented in Table 1. Participants (N = 40) were 25-63 years old (M = 46.95, SD =
9.81). Participants included more men (N = 25; 62.5%) than women (N = 15; 37.5%).
The majority of participants were African-American (N = 38; 95%), with the remainder
identifying as Caucasian (n = 1; 2.5%) and Hispanic (N = 1; 2.5%). Sixty-eight percent
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of the sample (N = 27) completed at least 12 years of education. The mean Fagerström
Test for Nicotine Dependence score was 5.5 (SD = 1.97) indicating an overall Moderate
level of nicotine dependence. Fifty-five percent of the sample (N = 22) was initially
randomized to the standard of care treatment condition; 45% (N = 18) were initially
randomized to the contingency management treatment condition.
Predictor Variables. Participants reported a mean BDI-II depression score of
15.1 (SD = 12.41) indicating an overall Mild level of depression. Measures of community
violence (The Things I Have Seen and Heard), intimate partner violence (Revised
Conflict Tactics Scale - Short Form), social support (Interpersonal Support Evaluation
List), and life satisfaction (Quality of Life Inventory) do not indicate clinical significance
thresholds and are described below.
Total possible TSH community violence scores range from 0-54, with greater
scores indicating more exposure to community violence. Participants reported a mean
community violence score of 28.25 (SD = 13.11). All participants reported exposure to
at least one lifetime community violence event. Specific violence items endorsed are
presented in Table 11.
Total possible CTS2S intimate partner violence scores range from 0-120, with
greater scores indicating more exposure to intimate partner violence. Participants
reported a mean partner violence score of 15.60 (SD = 14.30). Sixty percent of
participants reported at least one partner violence victimization event in the past year.
Specific violence victimization items endorsed are presented in Table 12. Sixty-eight
percent of participants reported at least one partner violence perpetration event in the
past year. Specific violence items endorsed are presented in Table 13.

33
Total possible ISEL social support scores range from 0-160, with higher scores
indicating greater perceived social support. Total social support scores reported in this
sample ranged from 61 to 147. Participants reported a mean total social support score
of 121.20 (SD = 22.00). ISEL social support subscales include Appraisal (perceived
availability of others to trust and confide in), Tangible support (perceived availability of
instrumental

help),

Self-Esteem

support

(perceived

positive

comparisons

in

interpersonal relationships), and Belongingness support (perceived sense of social
belongingness). Possible subscale scores range from 0-40. Participants reported a
mean Appraisal subscale score of 30.93 (SD = 6.16). The mean Tangible support
subscale score was 29.73 (SD = 6.10). The mean Self-Esteem support subscale score
was 29.58 (SD = 5.35). The mean Belongingness support subscale score was 30.98
(SD = 6.44). All four ISEL social support subscale scores were comparable, with means
ranging from 29.58 to 30.98. The ISEL total perceived social support score was used in
the current analyses.
Total possible life satisfaction scores on the Quality of Life Inventory range from 51 to 51 (with individual items endorsed on a scale from -3, or very dissatisfied, to 3,
very satisfied). Higher scores indicate greater life satisfaction. Total life satisfaction
scores in the current sample ranged from -33 to 51. Participants reported a mean total
life satisfaction score of 13.75 (SD = 21.61). Mean life satisfaction scores reported in
each of the 17 areas of functioning are presented in Table 14. As seen in Table 14,
participants reported the lowest life satisfaction scores in the following three areas:
Standard of Living (income, possessions such as cars or furniture, and expectations for
having financial needs met), Work (pay, surroundings, security, relationships with co-
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workers, and availability of needed equipment and supervision), and Health (being
physically fit and free from sickness, pain, or disability). The highest life satisfaction
scores were reported in the following three areas: Relationships with Children (getting
along with, helping, teaching, and caring for child/children), Friendships (number and
quality of close friends with mutual companionship, acceptance, trust, and support), and
Social Service (helping, encouraging, and promoting the welfare of others such as
through church, clubs, or volunteer groups).
Outcome Variables. Change scores (X-Y) were assessed for all outcome
variables with the exception of longest duration of abstinence (LDA). As previously
noted, cotinine scores are reported semi-quantitatively, with ordinal scores of 0-6 being
assigned based on cotinine concentrations. Of note, there is unequal variance within
each ordinally assigned level (e.g., a score of 0 indicates cotinine levels of 1-10 ng/mL,
while a score of 6 indicates cotinine levels of >1000 ng/mL). The mean baseline cotinine
score was 5.63 (SD = .93) indicating a high level of cigarette use at baseline. The mean
change in cotinine scores from baseline to Time 1 was .50 (SD = .18), and mean
change in cotinine scores from baseline to Time 2 was .55 (SD = .20). Higher change
scores indicate decreased cotinine levels from baseline to time point.
The mean past-month number of cigarettes smoked at baseline was 13.97 (SD =
1.09). Mean change in cigarette use from baseline to Time 1 was 8.29 (SD = .91), and
mean change in cigarette use from baseline to Time 2 was 9.12 (SD = 1.12). Higher
change scores indicate decreased cigarette use from baseline to time point. Participants
reported a mean LDA (longest string of consecutive days of smoking abstinence) score
of 10.43 (SD = 16.56) throughout the duration of treatment.
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Total Minnesota Nicotine Withdrawal Scale (MNWS) scores range from 0-60 with
higher scores indicating greater withdrawal. Mean change in MNWS withdrawal scores
at baseline was 20.33 (SD = 15.88). Mean change in withdrawal scores from baseline to
Time 1 was 4.0 (SD = 1.92), and mean change in withdrawal from baseline to Time 2
was 3.98 (SD = 2.06). Higher change scores indicate decreased withdrawal symptoms
scores from baseline to time point.
Total Questionnaire of Smoking Urges (QSU) scores range from 0-70 with higher
scores indicating more smoking urges. Mean QSU smoking urges scores at baseline
was 45.95 (SD = 15.37). Mean change in smoking urges from baseline to Time 1 was
21.33 (SD = 2.66), and mean change in smoking urges from baseline to Time 2 was
22.35 (SD = 2.66). Higher change scores indicate decreased smoking urges scores
from baseline to time point.
Total Reasons for Quitting Smoking (RFQ) scores range from 0-80 with higher
scores indicating greater motivations to quit smoking. The mean RFQ quitting
motivations score was 42.90 (SD = 15.72). Mean change in quitting smoking
motivations from baseline to Time 1 was -1.65 (SD = 1.92), and mean change in quitting
smoking motivations from baseline to Time 2 was .43 (SD = 2.64). Lower change scores
indicate increased motivations to quit smoking from baseline to time point.
Differences by Sociodemographic Variables. Differences on exposure to
community violence, exposure to interpersonal violence, depression scores, life
satisfaction, and perceived social support, as well as differences on the outcome
variables of cotinine, LDA, cigarette use, withdrawal, smoking urges, and motivations for
quitting smoking, were examined by socio-demographic variables (age, gender,
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ethnicity, education, and nicotine dependence), and initial treatment condition. These
tests were conducted to determine if there were significant group differences based on
baseline demographic and study characteristics. Comparisons were conducted using
analysis of variance (ANOVA). There were no significant differences in the predictor or
outcome variables based on age, ethnicity, education, nicotine dependence, or initial
treatment condition. Results showed a significant difference in community violence
exposure by gender (F(1, 38) = 4.53, p < .05), with men reporting greater community
violence exposure.
Primary Analyses
Effect of Violence, Depressive Symptoms, and Life Satisfaction on
Smoking Cessation. Hierarchical multiple regressions were used to assess the unique
effect of each predictor variable on each outcome variable while controlling for
differences explained by sociodemographic variables and initial treatment condition.
Variables were entered in two hierarchical blocks. For all regressions, the first block
contained primary predictor variables (community violence, and intimate partner
violence; depressive symptoms, and life satisfaction). In the second blocks,
sociodemographic and initial treatment condition variables (age, gender, education,
initial treatment condition assignment, and Fagerström nicotine dependence scores)
were entered. As 95% of the sample was African-American, ethnicity was not
associated with any predictor or outcome variables; thus, the sociodemographic
variable of ethnicity was excluded from all future regression analyses. Primary study
variables were entered in the first block to gain a better understanding of both the model
fit of the primary study variables, and the model fit of the primary variables while
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secondarily controlling for sociodemographic variables and initial treatment condition
(e.g., Newman & Thompson, 2003).
Regressions were run separately for violence variables (community violence, and
intimate partner violence), and mood/protective variables (depressive symptoms, and
life satisfaction). Five regressions were run with community violence and intimate
partner violence predicting each post-Phase 1 (initial smoking response) outcome
variable (change in cotinine, cigarette use, withdrawal, urges, and motivations for
quitting). Six regressions were run with community violence and intimate partner
violence predicting each post-Phase 2 (total cessation treatment response) outcome
variable (change in cotinine, cigarette use, withdrawal, urges, motivations for quitting,
and LDA). Five regressions were run with depressive symptoms and life satisfaction
predicting each post-Phase 1 outcome variable separately. Finally, six regressions were
run with depressive symptoms and life satisfaction predicting each post-Phase 2
outcome variable separately. In total, 22 regressions were run.
Initial smoking cessation response was assessed by analyzing intake predictor
variables and post-Phase 1 outcome variables, excluding the outcome of longest
duration of abstinence (LDA), which measured continuous abstinence throughout the
total 12-week treatment period (Phase 1 and Phase 2). Total cessation treatment
response was assessed by analyzing intake predictor variables and post-Phase 2
outcome variables. For both post-Phase 1 and post-Phase 2 outcome variables, change
scores (X-Y) were assessed from intake (X) to post-Phase 1 (Y) and 2 (Z) for the
variables of cotinine, withdrawal, urges, and motivations for quitting smoking.
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Treatment condition in Phase 1 was assessed as a predictor variable in both
post-Phase 1 and post-Phase-2 regressions. Though it would be ideal to analyze Phase
2 treatment condition in the post-Phase 2 analysis, Phase 2 treatment condition was
confounded by the role of initial treatment response in Phase 2 treatment assignments;
thus, initial (Phase 1) treatment condition alone was controlled for in analyses of both
post-Phase 1 and post-Phase 2 outcomes.
Effect of Violence on Initial Smoking Cessation. Results are presented in Table 3.
There were no significant effects of predictors on Post-Phase 1 (initial) change in
cotinine, withdrawal, or smoking urges (all ps > .05). There were significant effects of
predictors on initial change in motivations to quit smoking and cigarette use (described
below).
There was a significant effect of Block 1 (community violence and intimate
partner violence exposure) on change in cigarette use (F(2, 37) = 6.07, p < .05). Block 1
of this model explained 13.8% (R2) of the total variance in cigarette use. In Block 1,
intimate partner violence exposure significantly predicted initial cigarette use (β = -.37, p
< .05), with greater intimate partner violence exposure being related to increased
cigarette use relative to intake. Block 2, which contained sociodemographic and initial
treatment variables, was also significant (F(2, 37) = 2.92, p < .05). Block 2 did not
significantly explain increased variance in cigarette use from Block 1 (∆F = 2.11, p =
.09). In Block 2, partner violence remained significant (β = -.10, p < .05) and was related
to increased cigarette use. Gender was also significant (β = -.33, p = .05), with male
gender being related to reduced cigarette use.
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There was a significant effect of Block 1 (community violence and intimate
partner violence exposure) on initial change in motivations for quitting smoking (F(2, 37)
= 3.34, p < .05). Block 1 of this model explained 15.3% (R2) of the total variance in
motivations for quitting smoking. In Block 1, community violence exposure significantly
predicted initial motivations for quitting smoking (β = 2.49, p < .05), with greater
community violence exposure being related to decreased motivations to quit smoking
relative to intake. Block 2, which contained sociodemographic and initial treatment
variables, was not significant (p > .05).
Effect of Violence on Total Smoking Cessation. Results are presented in Table 4.
There were no significant effects of predictors on Post-Phase 2 (total treatment) change
in cotinine, cigarette use, withdrawal, urges, motivations for quitting smoking, or LDA (all
ps > .05).
Effect of Depressive Symptoms and Life Quality on Initial Smoking Cessation.
Results are presented in Table 5. There were no significant effects of predictors on
initial change in cotinine, urges, or motivations for quitting smoking (all ps > .05). There
were significant effects of predictors on initial change in withdrawal and cigarette use
(described below).
There was a significant effect of Block 2 (sociodemographic and initial treatment
condition variables) on initial change in cigarette use (F(2, 37) = 2.58, p < .05). Block 2
of this model explained 36% (R2) of the variance in initial treatment cigarette use, which
represented a significant increase in variance explained from Block 1 of the model (∆F =
3.50, p < .05). In Block 2 of this model, gender significantly predicted initial cigarette use
(β = -.33, p < .05), with male gender being related to reduced cigarette use relative to
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intake. Block 1 (depressive symptoms scores and life quality) was not significant (p >
.05).
There was a significant effect of depressive symptoms and life satisfaction
scores (Block 1) on initial change in withdrawal symptoms (F(2, 37) = 3.27, p < .05).
Block 1 (depressive symptoms and life satisfaction) of this model explained 15% (R2) of
the total variance in withdrawal from smoking. In Block 1, depressive symptoms scores
significantly predicted smoking withdrawal (β = 2.33, p < .05), with greater depressive
symptoms being related to reduced experience of initial withdrawal symptoms. Block 2,
which contained sociodemographic and initial treatment variables, was not significant (p
> .05).
Effect of Depressive Symptoms and Life Quality on Total Smoking Cessation.
Results are presented in Table 6. There were no significant effects of predictors on total
treatment change in cotinine, urges, motivations for quitting smoking, or LDA (all ps >
.05). There was a significant effect of predictors on total treatment change in withdrawal
(described below).
There was a significant effect of depressive symptoms and life satisfaction
scores (Block 1) on total treatment change in withdrawal (F(2, 37) = 3.62, p < .05).
Block 1 of this model explained 16.4% (R2) of the total variance in total treatment
smoking withdrawal. In Block 1, depressive symptoms scores significantly predicted
smoking withdrawal (β = 2.64, p < .05), with greater depressive symptoms being related
to reduced post-Phase 2 smoking withdrawal relative to intake. Block 2, which
contained sociodemographic and initial treatment variables, was not significant (p >
.05).
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Moderating Effect of Social Support. Hierarchical regressions were used to
assess the moderating effects of social support, as measured by the ISEL. This analysis
allowed for evaluation of both the independent and interactive effects of social support
on

all

outcome

variables

while

controlling

for

differences

explained

by

sociodemographic and initial treatment variables (Aiken & West, 1991).
Variables were entered into the regression equation by blocks. In the first block,
social support and primary predictor variables (community violence and intimate partner
violence; depressive symptoms and life quality) were entered. In the second block,
sociodemographic and initial treatment variables (age, gender, education, initial
treatment condition, and nicotine dependence scores) were added. The third step
added two-way interaction terms between social support and predictor variables (social
support by exposure to community violence, and social support by intimate partner
violence; social support by depressive symptoms, and social support by life
satisfaction). These regressions were run separately for each primary predictor variable.
This was done to reduce collinearity and increase power of analyses. Regressions were
run separately for each outcome variable. In total, 24 moderation regressions were run.
To determine if the interactions entered in the third block significantly added to
the variance in the given outcome variable, significant change in the F statistic was
examined (West & Aiken, 1997, 1991). If the third model yielded significant change,
social support and the given predictor significantly interacted to predict the outcome
variable. Squared semi-partial correlations were also examined to determine the unique
effects of each predictor and interaction.
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Moderating Effect of Social Support on Violence in Predicting Initial Smoking
Cessation. There were no independent or moderated effects on initial change in
cotinine, withdrawal, urges, or motivations for quitting smoking (all ps > .05). There were
significant model effects for initial change in cigarette use only (described below and
presented in Table 7). Results showed no significant moderation effects for any
outcome variables.
There was a significant effect of the model containing community violence, social
support, and sociodemographic and treatment variables, on initial treatment change in
cigarette use (Table 7). Block 1 (community violence and social support) was not
significant (p > .05). There was a significant effect of Block 2 (sociodemographic and
initial treatment variables added) on initial treatment cigarette use (F(7, 32) = 2.40, p <
.05). Block 2 of this model explained 34% (R2) of variance in initial change in cigarette
use, and significantly increased variance explained from Block 1 (∆F = 3.35, p < .05). In
Block 2 of this model, gender significantly predicted initial change in cigarette use (β = .34, p < .05), with male gender being related to decreased cigarette use (measured
relative to intake). Block 3 (community violence by social support interaction term
added) was significant (F(8, 31) = 2.23, p < .05). Block 3 of this model explained 37%
(R2) of variance in initial change in cigarette use, but did not significantly increase
variance explained from Block 1 (∆F = 1.03, p > .05). In Block 3 of this model, gender
alone significantly predicted initial change in cigarette use (β = -.37, p < .05), with male
gender being related to decreased cigarette use from intake.
There was a significant effect of the model containing intimate partner violence,
social support, and sociodemographic and treatment variables, on initial change in
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cigarette use (Table 7). Block 1 (intimate partner violence and social support) was not
significant (p > .05). Block 2 of this model added sociodemographic and initial treatment
variables, and showed a significant effect on initial change in cigarette use (F(7, 32) =
2.43, p < .05). Block 2 of this model explained 35% (R2) of variance in total treatment
cigarette use, but did not significantly increase variance explained from Block 1 (∆F =
2.03, p > .05). In Block 2 of this model, gender significantly predicted initial change in
cigarette use (β = -.31, p <.05), with male gender being related to decreased cigarette
use relative to intake. Block 3 (intimate partner violence by social support interaction
term added) was significant (F(8, 31) = 2.32, p < .05), and explained 37% (R2) of
variance in total treatment cigarette use, but did not significantly increase variance
explained from Block 2 (∆F = 1.36, p > .05). In Block 3 of this model, gender alone
significantly predicted initial change in cigarette use (β = -.32, p < .05), with male gender
being related to decreased cigarette use from intake.
Moderating Effect of Social Support on Violence in Predicting Total Smoking
Cessation. There were no independent or moderated effects on total treatment change
in cotinine, cigarette use, withdrawal, urges, motivations for quitting smoking, or LDA (all
ps > .05). Results showed no significant moderation effects for any outcome variables.
Moderating Effect of Social Support on Depressive Symptoms and Life Quality in
Predicting Initial Smoking Cessation. There were no independent or moderated effects
on initial change in cotinine, urges, or motivations for quitting smoking (all ps > .05).
There were significant model effects for initial change in withdrawal and cigarette use
(described below and presented in Tables 8-9). Results showed no significant
moderation effects for any outcome variables.
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There was a significant effect of the model containing depressive symptoms,
social support, and sociodemographic and treatment variables, on initial change in
withdrawal symptoms (Table 8). Block 1 (depressive symptoms and social support)
significantly predicted initial change in withdrawal (F(2, 37) = 3.28, p < .05), and
explained 15% (R2) of the variance in initial smoking withdrawal. In Block 1 of this
model, depressive symptoms scores significantly predicted initial change in withdrawal
symptoms (β = 2.10, p < .05), with higher depression scores being related to reduced
withdrawal relative to intake. Block 2 of this model added sociodemographic and initial
treatment variables, and was not significant (p > .05); however, depression scores
remained a significant predictor in this block (β = 2.14, p < .05). Block 3 of this model
added the interaction of social support and depressive symptoms, and was not
significant (p > .05).
There was a significant effect of the model containing depressive symptoms,
social support, and sociodemographic and treatment variables, on initial change in
cigarette use (Table 9). Block 1 (depressive symptoms and social support) was not
significant. There was a significant effect of Block 2 (sociodemographic and initial
treatment variables added) on initial treatment change in cigarette use (F(7, 32) = 2.57,
p < .05). Block 2 of this model explained 36% (R2) of variance in initial cigarette use,
and significantly increased variance explained from Block 1 (∆F = 3.57, p < .05). In
Block 2 of this model, gender (β = -.33, p < .05) and education (β = -.33, p < .05)
significantly predicted initial cigarette use, with male gender and higher level of
education being related to decreased cigarette use relative to intake. There was a
significant effect of Block 3 on initial change in cigarette use (F(8, 31) = 2.31, p < .05).
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Block 3 of this model explained 37% (R2) of variance in initial change in cigarette use,
but did not significantly increase variance explained from Block 2 (∆F = .64, p > .05). In
Block 3, gender (β = -.38, p < .05) and education (β = -.34, p < .05) significantly
predicted initial change in cigarette use. Male gender and higher education level related
to decreased cigarette use relative to intake.
There was a significant effect of the model containing life satisfaction, social
support, and sociodemographic and treatment variables, on initial change in cigarette
use (Table 9). Block 1 (life satisfaction and social support) was not significant (p > .05).
Block 2 of this model added sociodemographic and initial treatment variables. There
was a significant effect of Block 2 on initial change in cigarette use (F(7, 32) = 2.57, p <
.05). Block 2 of this model explained 36% (R2) of the variance in initial change in
cigarette use and significantly increased variance explained (∆F = 3.48, p < .01). In
Block 2 of this model, gender (β = -.34, p < .05) and education (β = -.33, p < .05)
significantly predicted initial cigarette use, with male gender and higher level of
education being related to decreased initial cigarette use relative to intake. Block 3
added the interaction term between social support and depressive symptoms. There
was a significant effect of Block 3 on total treatment cigarette use (F(8, 31) = 2.36, p <
.05). Block 3 of this model explained 38% (R2) of variance in initial cigarette use, but did
not significantly increase explained variance (∆F = .90, p > .05). In Block 3, gender (β =
-.38, p < .05) and education (β = -.35, p < .05) remained significant predictors, with male
gender and higher level of education being related to decreased cigarette use relative to
intake.
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Moderating Effect of Social Support on Depressive Symptoms and Life Quality in
Predicting Total Smoking Cessation. There were no independent or moderated effects
on total treatment change in cotinine, cigarette smoking, urges, motivations for quitting
smoking, or LDA (all ps > .05). There were significant model effects for total treatment
change in withdrawal only (described below and presented in Table 10). Results
showed no significant moderation effects for any outcome variables.
There was a significant effect of the model containing depressive symptoms,
social support, and sociodemographic and treatment variables, on total treatment
change in withdrawal symptoms (Table 10). Block 1 (depressive symptoms and social
support) significantly predicted initial change in withdrawal (F(2, 37) = 3.32, p < .05),
and explained 15.2% (R2) of variance in total smoking withdrawal. In Block 1 of this
model, depressive symptoms scores significantly predicted total treatment change in
withdrawal symptoms (β = .34, p < .05), with greater depression being related to
reduced post-treatment withdrawal relative to intake. Block 2 of this model added
sociodemographic and initial treatment variables, and was not significant (p > .05).
Block 3 of this model added the interaction of social support and depressive symptoms,
and was not significant (p > .05).
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CHAPTER 4: DISCUSSION
The purpose of this study was to investigate the impact of protective and risk
factors on smoking cessation among PLWHA in smoking cessation treatment.
Specifically, this study examined the roles of two prevalent components of violence
among this population, community violence and intimate partner violence, as well as
two variables related to well-being, depression and life satisfaction. This study also
assessed the influence of the protective factor of social support on smoking cessation,
including moderating effects of social support on violence and well-being variables in
predicting smoking cessation outcomes. In addition to primary predictor variables, this
study accounted for sociodemographic factors that are often associated with smoking
cessation treatment outcomes. These factors included age, gender, education, baseline
nicotine dependence scores, and initial treatment condition assignment in the larger
clinical trial.
Outcome variables were a range of smoking indicators, including withdrawal
symptoms, urges to smoke, motivations for quitting smoking, cotinine scores, selfreported cigarette use, and longest duration of continuous abstinence (longest
consecutive number of days not smoking). The purpose of including this range of
smoking cessation variables was exploratory. These particular smoking indicators were
chosen because they are central to both the experience (withdrawal, urges, motivations
for quitting) and the assessment (cotinine, cigarette use, LDA) of quitting smoking,
particularly among clinically high-risk groups (Leventhal, Ameringer, Osborn, Zvolensky,
and Langdon, 2013; Leventhal et al., 2013; Reid & Ledgerwood, 2015; Weinberger,
McKee, & George, 2012; Ziedonis et al., 2008).
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Significant Findings
This study found that increased community violence predicted reduced
motivations for quitting smoking (relative to intake) after the first phase of treatment.
Increased intimate partner violence was related to increased cigarette use (relative to
intake) after the first phase of treatment. These findings suggested that discrete
components of violence exposure are differentially associated with smoking outcomes,
particularly in the beginning of smoking cessation treatment. Increased experience of
community violence appears to be related to a proxy of cigarette use (i.e., motivations
for quitting smoking), while interpersonal violence is related to actual increase in
smoking behaviors (i.e., number of cigarettes smoked). It is possible that interpersonal
violence is experienced as being localized to the relationship, and thus predicts a more
acute coping need, achieved through smoking. This is in-line with cross-cultural
research showing that domestic violence is associated with tobacco use, particularly in
areas where greater rates of violence are reported (Ackerson, Kawachi, Barbeau, &
Subramanian, 2007).
In contrast, community violence may be experienced more systemically, which
could impact distal smoking behaviors. Systemic stress related to chronic experiences
of

community

violence

across

multiple domains

(e.g.,

neighborhood,

home,

school/work) may increase hopelessness, which may then mediate between community
violence and motivations to quit smoking. Challenges related to these varying forms of
violence are of particular importance as 100% of the current sample reported exposure
to at least one lifetime community violence event, and 60% of the current sample
reported experiencing partner violence victimization in the last year. Specific item
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endorsements are illustrated in Table 11 (community violence) and Table 12 (intimate
partner violence).
Relationships between partner violence and increased cigarette use, and
community violence and reduced quitting motivations, were found after the first phase of
treatment only. Phase 1 (initial) treatment condition alone was controlled for in the
present analyses, as Phase 2 treatment condition was confounded with the role of initial
treatment response in Phase 2 treatment assignments. It is likely that because
individuals are assigned to different treatment conditions in Phase 2 based on their
response to treatment in Phase 1, Phase 2 treatment assignment was predictive of total
treatment smoking cessation success.
Participants who reported relatively greater depressive symptoms at baseline
were more likely to demonstrate reductions in smoking withdrawal after both the first
and second phases of treatment (relative to intake). This finding was congruent with
previous literature showing that smokers with greater depression scores at baseline
report significantly different withdrawal experience than smokers in the same treatment
with lower depressive scores at baseline (Reid & Ledgerwood, 2015). Though it could
be argued that withdrawal is experienced as a result of achieving abstinence from
smoking, the previous study showed differences in withdrawal experience despite nondifferential levels of tobacco use throughout treatment (assessed through expired
carbon monoxide).
In order to further understand these differences in withdrawal experience as a
function of depression scores, means and group differences for withdrawal were
evaluated by depression score categorization. In the present study, greater depressive
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symptoms scores at intake were associated with greater withdrawal sensitivity at intake
(r = .76, p < .01), post-Phase 1 (r = .57, p < .01), and post-Phase 2 (r = .50, p < .01). To
better evaluate differences in withdrawal experience in a clinically interpretable manner,
depressive symptoms were dichotomized into low (scores < 13; n = 22) versus high
scores (scores > 13; n = 18) based on BDI-II clinical significance cut-offs (with scores of
0 to 13 representing Minimal depression, and 14 and above representing Moderate to
Severe depression). Mean scores and group differences demonstrated that mean
withdrawal scores were significantly higher among individuals reporting greater
depressive symptoms, but that withdrawal decreased more for high-depression scorers
(compared to low-depression scorers) between time points (see Figure 1).
It is possible that smokers with higher depression scores demonstrated greater
reductions in withdrawal throughout treatment by virtue of reporting significantly higher
withdrawal scores at baseline; those with greater baseline depression scores reported
almost four-fold higher withdrawal scores than those with low baseline depression
scores. Additionally, unmeasured components of treatment, in particular, treatment of all
participants with bupropion (commonly prescribed as an antidepressant), may have
secondarily aided in reducing depressive symptoms. Buproprion treatment, though not
prescribed in the present study for depression symptoms, may be associated with
greater changes in withdrawal experience specifically for smokers with greater baseline
depressive symptoms, and relatedly greater baseline withdrawal sensitivity.
Increased initial sensitivity to withdrawal among individuals who report mood
instability is potentially associated with decreased distress tolerance, or the ability to
experience and manage negative internal states, as well as discomfort intolerance, or
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the ability to withstand uncomfortable physical sensations (Ellis, Vanderling, & Beevers,
2012; Schmidt & Lerew, 1998; Williams, Thompson, & Andrews, 2013). It is thus
possible that individuals who report high depression scores have a more aversive initial
experience of withdrawal from tobacco. PLWHA who have co-occurring tobacco use
disorder and depression might then be increasingly vulnerable to greater dysphoria
during initial withdrawal, particularly when withdrawal is experienced in combination with
disease-related physical discomfort.
The sociodemographic variable of male gender was related to greater reductions
in cigarette use after the first phase of treatment (in models testing both mood and life
satisfaction, and violence). This is congruent with men reporting more prevalence and
severity of tobacco use, particularly among PLWHA (CDC, 2015; Mdodo et al., 2015;
WHO, 2007), but demonstrating greater abstinence success across a variety of
cessation treatments (Carlson et al., 2002; McKee et al., 2005; Scharf & Shiffman,
2004; Wetter et al., 1999). One smoking cessation study in particular showed prominent
gender differences in a treatment that incorporated bupropion and behavioral
counseling (Collins et al., 2004). Collins and colleagues (2004) not only found that men
were more likely to quit and remain abstinent after treatment and at follow-up, but also
identified a gender interaction whereby women benefitted more from bupropion
treatment if they were light smokers, and men benefitted more from bupropion if they
were heavy smokers.
It is then possible that women who reduced smoking as a result of their
engagement in smoking treatment were increasingly benefitted by the bupropion
component of treatment as treatment continued (i.e., equally reduced cigarette use in
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the second phase of treatment). As noted above, tailored treatment assignment in the
second phase of treatment may have additionally been related to increased smoking
success across participant groups in the second phase of treatment.
There were no independent or moderating effects of social support on smoking
outcome variables. This could be related to the socially complex nature of HIV/AIDS. As
a result of social stigma associated with HIV status, PLWHA are less likely to disclose
their status to friends and family (Sayles et al., 2007). This may indicate less access to
instrumental and emotional support for challenges PLWHA uniquely face, even if
reports of broad social support are high among this group. That is to say, PLWHA may
experience lower-quality social support even when support is present. Findings are
congruent with research showing weak associations between social support and health
among PLWHA (Ironsen et al., 2005; Ironson & Hayward, 2008). However, rather than
indicating reduced need for social support among smokers living with HIV/AIDS,
findings support the notion that different forms of support, for instance peer support,
may be particularly important among this group. Literature has shown effective peerbased interventions for depressive symptoms among PLWHA with high levels of
substance use (Simoni, Pantalone, Plummer, & Huang, 2007).
Implications
Based on the relationship between community violence and quitting motivations,
and intimate partner violence and cigarette use, it is important to assess interpersonal
and community violence exposure among smokers prior to cessation treatment. This is
specifically important among smokers with HIV/AIDS, as base rates of violence and
trauma are greater among this population (Matchinger, Wilson, Haberer, & Weiss,
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2012). Every individual in the current sample reported community violence exposure,
with the most prevalently endorsed experiences including witnessing police arrests,
hearing gunfire, witnessing drug use and drug deals in the neighborhood, and
witnessing and personally experiencing physical assault (Table 11). The least
prevalently experienced community violence events (e.g., experiencing threats of being
stabbed, or killed, and witnessing someone get shot or stabbed in the home) were still
endorsed by 15-30% of the sample.
Although fewer participants endorsed partner violence exposure (potentially
partially due to the necessity of having had a recent romantic partnership), the majority
of the sample (60%) still reported violence victimization enacted by intimate partners in
the past year (Table 12). The most prevalently reported items included experiences of
being verbally (i.e., insulted, swore, or shouted at) assaulted, and physically injured
(e.g., experiencing a sprain, bruise, small cut, or physical pain after an altercation).
Relatively “severe” partner violence experiences were endorsed by 10% of the sample,
and included needing medical attention after an altercation, being forced (through
hitting, holding down, or use of a weapon) to have sex, and being forced to have sex
without a condom (without physical force). Severe sexually violent experiences may be
directly related to HIV disease status, and thus potentially traumatizing on several
levels.
Sixty-eight percent of the sample reported perpetrating violence on intimate
partners in the past year (Table 13). Prevalence rates of specific perpetration events
were comparable to the prevalence of victimization events. The most prevalently
reported perpetration event was insulting, swearing, shouting, or yelling at an intimate
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partner (65%). Relatively severe violence perpetration experiences were endorsed by
10-12.5% of the sample.
For smokers reporting high levels of intimate partner violence exposure,
therapeutic attention should be given to adaptive coping (Brady et al., 2009; Crane,
Hawes, & Weinberger, 2013). Two forms of adaptive coping in particular, behavioral
coping (e.g., problem solving), and cognitive coping (e.g., positive reappraisals), have
been found to mitigate the influence of violence victimization on substance use (Brady
et al.). For individuals with significant community violence experience, intrinsic
motivations to reduce or abstain from smoking should be evaluated. Motivational
interviewing is one evidence-based approach that would address conscious and
unconscious motivations to fully engage in treatment to reduce smoking behaviors (Lai,
Cahill, Qin, Tang, 2010). The 5As/Rs counseling model used in the clinical trial that
houses the present study emphasizes motivation and behavioral skills in reducing
smoking (USPHS), and could additionally be used in a targeted fashion when
individuals report interpersonal or community violence experiences.
Based on findings related to different patterns of withdrawal among HIV-positive
smokers who report greater versus lower depression scores, it is important for clinicians
to assess psychological distress, particularly depression, prior to engaging smokers in
smoking cessation treatment. It may also be useful to tailor components of treatment to
the aversive withdrawal experience PLWHA may uniquely face, particularly at the outset
of smoking treatment. Interventions that emphasize acceptance and tolerance are
empirically based approaches to the treatment of substance use among individuals with
mood symptoms (Brewer, Bowen, Smith, Marlatt, & Potenza, 2010; Dimeff & Linehan,

55
2008; Linehan et al., 2002). This is particularly relevant given increased reports of mood
disorders among PLWHA (Ferrando & Freyberg, 2008; Reynolds, 2009).
Limitations
Findings should be considered in the context of study limitations. The study’s
sample size (n = 40) was small, limiting the detection of the full strength of relationships
among violence, mood, life satisfaction, social support, and smoking cessation
indicators. The sample was also unevenly distributed across gender and ethnic groups,
with more men (n = 25) than women, and most participants identifying as AfricanAmerican (n = 38). In addition, this sample included no individuals that identified as a
gender other than man or woman. These distributions are particularly important when
assessing experiences that are known to vary by gender and ethnicity, including
exposure to community violence and intimate partner violence (Foster, Kuperminc, &
Price, 2004; Saewyc et al., 2009). It will be important to test the present hypotheses
with a larger, more equally distributed sample in order to provide firmer basis for the
present study’s clinical implications. A larger, evenly distributed sample would also allow
for a deeper analysis of the specific subcomponents of community violence, intimate
partner violence, and social support that tobacco-using PLWHA may uniquely report.
An additional limitation as previously specified was the inability to control for
Phase 2 treatment condition assignment in analyses of Phase 2 treatment outcomes.
This was due to the confounding nature of Phase 2 assignment with Phase 1 treatment
response. Finally, this study relies on self-report to measure constructs that may be
particularly influenced by social desirability (e.g., partner violence, community violence,
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social support). Of note, self-reported cigarette use behaviors (through TLFB-C) were
compared to, and congruent with, urinary cotinine levels.
Directions for Future Research
Future research should assess mechanisms underlying relationships between
community and interpersonal violence and smoking indicators. Specifically, research
should explore mediational relationships between cognitive and emotional helplessness
and reduced motivations for quitting smoking. In a larger sample, it would also be
relevant to examine subcomponents of each form of violence. It is possible that physical
versus emotional partner violence indicates different outcomes for smoking, particularly
given that HIV status may be more related to a particular form of partner violence
(Burke, Thieman, Gielen, O’Campo, & McDonnell, 2005; Maman et al., 2002). The
Conflict Tactics Scale used in the present analyses has the capacity in a large,
distributed sample to assess physical versus emotional conflict, frequency, severity, and
perpetrator experience. Future research could additionally stratify a large sample by
gender and sexual orientation to examine whether differential patterns of violence
exposure hold among subsamples of gender and orientation.
Conclusions
This dissertation is an important exploration of the impact of violence, mood, and
protective factors on smoking cessation experience in a modest sample of HIV-positive
smokers undergoing smoking cessation treatment. This study’s findings revealed
important linkages between community violence exposure and motivations for quitting
smoking, as well as between increased depressive symptoms and patterns of smoking
withdrawal among HIV-positive smokers. Findings also provided prevalence data on
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various violence events experienced in the community and within intimate partnerships.
Continued investigations into risk and protective factors would deepen clinical insight
and knowledge about therapeutic approaches for a population of smokers with
heightened clinical and medical risk.
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Table 1
Descriptive Statistics
Study Variables
Socio-demographic Variables
Age
Gender
Male
Female
Ethnicity
African-American
Caucasian
Hispanic
Education (years)
Nicotine Dependence
Treatment Assignment
Standard
Contingency Management

Mean (SD)

Percentage

Sample Size

62.5
37.5

40
40
25
15

46.95 (9.81)

12.15 (1.42)
5.50 (1.97)

95
2.5
2.5
67.5

55.0
45.0

38
1
1
40
40
39
22
18

Predictor Variables
Community Violence
Intimate Partner Violence
BDI
Quality of Life
Social Support

28.25 (13.11)
15.60 (14.30)
15.10 (12.41)
13.75 (21.61)
121.20 (22.00)

40
40
40
40
40

Outcome Variables
Cotinine Intake
Cotinine Change Time 1
Cotinine Change Time 2
Cigarette Use Intake
Cigarette Use Change Time 1
Cigarette Use Change Time 2
MNWS Intake
MNWS Change Time 1
MNWS Change Time 2
QSU Intake
QSU Change Time 1
QSU Change Time 2
RFQ Intake
RFQ Change Time 1
RFQ Change Time 2
LDA

5.63 (.93)
.50 (.18)
.55 (.20)
13.97 (1.09)
8.29 (.91)
9.12 (1.12)
20.33 (15.88)
4.00 (1.92)
3.98 (2.06)
45.95 (15.37)
21.33 (2.66)
22.35 (2.66)
42.90 (15.72)
-1.65 (1.92)
.43 (2.64)
10.43 (16.56)

40
40
40
40
40
40
40
40
40
40
40
40
40
40
40
40
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Table 2
Bivariate Correlations
Primary Variables
1 Comm.Violence
2 Partn. Violence
3 BDI
4 Quality of Life
5 Social Support
6 Cot. Change T1
7 Cot. Change T2
8 Cig. Use Ch T1
9 Cig. Use Ch T2
10 MNWS Ch T1
11 MNWS Ch T2
12 QSU Ch T1
13 QSU Ch T2
14 RFQ Ch T1
15 RFQ Ch T2
16 LDA

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

.03

.40*
.10

-.16
-.21
-.50**

-.24
-.03
-.47**
.55***

-.10
.09
-.16
.12
.17

-.10
.06
-.09
.03
-.02
.68***

-.01
-.37*
.06
-.11
-.03
.37*
.08

-.01
-.18
.04
-.14
-.15
.31
.09
.83***

.18
.11
.39*
-.16
-.22
.11
.03
.25
.23

.12
.05
.38*
-.08
-.25
.00
-.03
.15
.13
.89***

-.10
-.13
-.04
.23
.17
.27
.16
.35*
.33*
.00
-.06

-.02
-.18
-.09
.24
.09
.25
.14
.20
.16
.00
.05
.75***

.38*
.10
.23
.01
-.08
-.02
-.08
.02
-.22
.10
.08
-.20
-.33*

.22
-.17
.08
-.09
-.22
.07
.10
.03
-.14
.02
.04
-.29
-.26
.58**

-.07
-.14
-.04
-.10
.12
.49**
.46**
.46**
.47**
.18
.04
.23
.15
-.34*
-.23

Note. *p < .05; **p < .01; ***p < .001. All outcome scores reported are change scores calculated
from Intake scores.
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Table 3
Multivariate Regression Effects of Violence on Time 1 Smoking Cessation Change
Scores
Predictor Variable
Explaining cotinine
scores
Block 1
Community violence
Partner violence
Block 2
Community violence
Partner violence
Age
Gender
Education
Initial treatment
Nicotine dependence
Explaining cigarette
use
Block 1
Community violence
Partner violence
Block 2
Community violence
Partner violence
Age
Gender
Education
Initial treatment
Nicotine dependence

Beta

SE

t

p

-.10
.09

.01
.01

-.62
.55

.54
.58

-.06
.21
-.34
-.13
-.14
.19
.23

.02
.02
.02
.44
.16
.41
.11

-.30
1.01
-1.78
-.68
-.70
1.08
1.18

.77
.32
.08
.50
.49
.29
.25

.02
-.37

.07
.06

.02
-2.46

.98
.02

-.05
-.10
.11
-.33
-.26
.20
.19

.07
.07
.10
1.90
.69
1.79
.49

-.33
-2.32
.63
-2.03
-1.54
1.26
1.10

.74
.04
.53
.05
.13
.22
.28

R2 (F)

.14 (6.07)*
Explaining withdrawal
Block 1
Community violence
Partner violence
Block 2
Community violence
Partner violence
Age
Gender
Education
Initial treatment
Nicotine dependence
Explaining urges

.18
.10

.15
.14

1.11
.63

.27
.54

.25
.22
.02
.03
-.24
.01
.02

.18
.18
.25
4.74
1.73
4.47
1.23

1.32
1.03
.09
.06
-1.17
.06
.11

.20
.31
.93
.95
.25
.95
.91
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Block 1
Community violence
Partner violence
Block 2
Community violence
Partner violence
Age
Gender
Education
Initial treatment
Nicotine dependence
Explaining motivations
for quitting smoking
Block 1
Community violence
Partner violence
Block 2
Community violence
Partner violence
Age
Gender
Education
Initial treatment
Nicotine dependence

-.09
-.13

.21
.19

-.53
-.79

.60
.44

-.11
-.04
.15
-.13
-.17
-.07
-.08

.24
.25
.34
6.54
2.39
6.18
1.70

-.58
-.17
.76
-.67
-.83
-.39
-.40

.57
.87
.45
.51
.41
.87
.69

.38
.09

.14
.13

2.49
.61

.02
.55

.29
.08
.02
-.20
.11
-.03
.06

.16
.17
.23
4.44
1.62
4.19
1.16

1.92
.38
.12
-1.09
.60
-.16
.33

.04
.70
.90
.28
.55
.87
.74
.15 (3.34)*

Note. *p < .05; **p < .01; ***p < .001. All outcome scores reported are change scores from
intake to Time 1. Standardized beta (β) coefficients and unstandardized standard error (SE)
coefficient values are reported. Final R2 and F statistics are reported for significant models.
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Table 4
Multivariate Regression Effects of Violence on Time 2 Smoking Cessation Change
Scores
Predictor Variable
Explaining cotinine
scores
Block 1
Community violence
Partner violence
Block 2
Community violence
Partner violence
Age
Gender
Education
Initial treatment
Nicotine dependence
Explaining cigarette
use
Block 1
Community violence
Partner violence
Block 2
Community violence
Partner violence
Age
Gender
Education
Initial treatment
Nicotine dependence
Explaining withdrawal
Block 1
Community violence
Partner violence
Block 2
Community violence
Partner violence
Age
Gender
Education
Initial treatment
Nicotine dependence
Explaining urges
Block 1

Beta

SE

t

p

-.11
.06

.02
.02

-.64
.38

.52
.71

-.08
.19
-.11
-.01
-.14
.25
-.01

.02
.02
.03
.50
.18
.47
.13

-.40
.88
-.54
-.01
-.68
1.33
-.04

.69
.39
.59
.10
.50
.19
.97

.01
-.18

.09
.08

.08
-1.11

.94
.27

-.03
.14
.20
-.33
-.34
.13
.22

.09
.09
.12
2.39
.87
2.25
.62

-.18
.79
1.19
-1.99
-1.97
.83
1.26

.86
.44
.24
.06
.06
.41
.22

.12
.05

.16
.15

.73
.30

.47
.77

.22
.08
.01
.11
-.17
-.16
.15

.19
.19
.26
5.06
1.84
4.78
1.32

1.19
.38
.07
.59
-.85
-.89
.75

.24
.71
.94
.56
.40
.38
.46

R2 (F)
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Community violence
Partner violence
Block 2
Community violence
Partner violence
Age
Gender
Education
Initial treatment
Nicotine dependence
Explaining motivations
for quitting smoking
Block 1
Community violence
Partner violence
Block 2
Community violence
Partner violence
Age
Gender
Education
Initial treatment
Nicotine dependence
Explaining LDA
Block 1
Community violence
Partner violence
Block 2
Community violence
Partner violence
Age
Gender
Education
Initial treatment
Nicotine dependence

-.09
-.18

.21
.19

-.11
-1.12

.91
.27

.05
-.18
-.17
.07
-.07
.01
.02

.24
.25
.35
6.62
2.41
6.23
1.72

.25
-.86
-.85
.35
-.37
.05
.09

.81
.39
.40
.73
.72
.96
.93

.23
-.18

.20
.18

1.46
-1.12

.15
.27

.30
-.18
-.06
.12
-.01
.01
.23

.23
.24
.33
6.28
2.29
5.93
1.63

1.65
-.88
-.32
.66
-.01
.01
1.18

.11
.39
.75
.51
.99
.10
.25

-.06
-.13

.21
.19

-.38
-.82

.71
.42

.01
.14
-.03
.06
-.37
.40
-.11

.22
.22
.31
5.88
2.14
5.55
1.53

.08
.73
-.14
.31
-1.99
2.38
-.58

.94
.47
.89
.76
.06
.02
.57

Note. *p < .05; **p < .01; ***p < .001. All outcome scores reported are change scores from
intake to Time 2. Standardized beta (β) coefficients and unstandardized standard error (SE)
coefficient values are reported. Final R2 and F statistics are reported for significant models.
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Table 5
Multivariate Regression Effects of Mood and Life Quality on Time 1 Smoking Cessation
Change Scores
Predictor Variable
Explaining cotinine
Block 1
Depressive symptoms
Quality of life
Block 2
Depressive symptoms
Quality of life
Age
Gender
Education
Initial treatment
Nicotine dependence
Explaining cigarette use
Block 1
Depressive symptoms
Quality of life
Block 2
Depressive symptoms
Quality of life
Age
Gender
Education
Initial treatment
Nicotine dependence

Beta

SE

t

p

-.14
.06

.02
.01

-.72
.30

.48
.77

-.05
.04
-.34
-.07
-.05
.12
.21

.02
.01
.02
.42
.14
.40
.12

-.23
.21
-1.69
-.42
-.32
.69
1.02

.82
.84
.10
.70
.75
.49
.32

.01
-.10

.09
.05

.03
-.54

.98
.59

.09
-.08
.07
-.33
-.33
.24
.22

.08
.04
.10
1.76
.58
1.71
.51

.51
-.45
.38
-2.18
-2.28
1.60
1.29

.61
.65
.71
.04
.03
.12
.21

R2 (F)

.36 (2.58)*
Explaining withdrawal
Block 1
Depressive symptoms
Quality of life
Block 2
Depressive symptoms
Quality of life
Age
Gender
Education
Initial treatment
Nicotine dependence

.41
.05

.17
.10

2.33
.27

.03
.79

.46
.06
-.08
.03
-.10
.05
.12

.19
.11
.24
4.22
1.39
4.10
1.21

2.35
.29
-.43
.02
-.60
.27
.62

.03
.77
.67
.99
.56
.79
.54
.15 (3.27)*

Explaining urges
Block 1
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Depressive symptoms
Quality of life
Block 2
Depressive symptoms
Quality of life
Age
Gender
Education
Initial treatment
Nicotine dependence
Explaining motivations
for quitting smoking
Block 1
Depressive symptoms
Quality of life
Block 2
Depressive symptoms
Quality of life
Age
Gender
Education
Initial treatment
Nicotine dependence

.10
.28

.25
.14

.52
1.50

.61
.14

.06
.28
.19
-.09
-.20
-.09
-.07

.27
.15
.34
5.10
1.96
5.79
1.71

.28
1.45
.93
-.54
-1.21
-.53
-.34

.79
.16
.36
.59
.23
.59
.73

.31
.17

.18
.10

1.70
.90

.10
.37

.29
.18
.01
-.26
.22
.00
.11

.19
.11
.24
4.20
1.38
4.08
1.20

1.49
.94
.04
-1.54
1.34
.03
.58

.15
.36
.97
.13
.19
.98
.57

Note. *p < .05; **p < .01; ***p < .001. All outcome scores reported are change scores from
intake to Time 1. Standardized beta (β) coefficients and unstandardized standard error (SE)
coefficient values are reported. Final R2 and F statistics are reported for significant models.
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Table 6
Multivariate Regression Effects of Mood and Life Quality on Time 2 Smoking Cessation
Change Scores
Predictor Variable
Explaining cotinine
Block 1
Depressive symptoms
Quality of life
Block 2
Depressive symptoms
Quality of life
Age
Gender
Education
Initial treatment
Nicotine dependence
Explaining cigarette use
Block 1
Depressive symptoms
Quality of life
Block 2
Depressive symptoms
Quality of life
Age
Gender
Education
Initial treatment
Nicotine dependence
Explaining withdrawal
Block 1
Depressive symptoms
Quality of life
Block 2
Depressive symptoms
Quality of life
Age
Gender
Education
Initial treatment
Nicotine dependence

Beta

SE

t

p

-.10
-.03

.20
.01

-.52
-.13

.61
.90

-.06
-.04
-.12
.05
-.07
.19
-.03

.02
.01
.03
.48
.16
.46
.14

-.26
-.20
-.58
.29
-.41
1.03
-.12

.79
.84
.57
.78
.68
.31
.90

-.04
.16

.11
.06

-.22
.85

.83
.40

.02
-.12
.16
-.30
-.30
.11
.22

.10
.06
.13
2.24
.73
2.17
.64

.10
-.71
.92
-1.93
-1.99
.71
1.25

.92
.48
.36
.06
.06
.49
.22

.46
.16

.18
.11

2.64
.89

.01
.38

.54
.19
-.08
.07
-.10
-.10
.28

.20
.11
.25
4.32
1.42
4.20
1.24

2.89
1.06
-.41
.43
-.64
-.59
1.47

.01
.30
.68
.67
.53
.56
.15

R2 (F)

.16 (3.62)*
Explaining urges
Block 1
Depressive symptoms

.04

.25

.23

.82
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Quality of life
Block 2
Depressive symptoms
Quality of life
Age
Gender
Education
Initial treatment
Nicotine dependence
Explaining motivations
for quitting smoking
Block 1
Depressive symptoms
Quality of life
Block 2
Depressive symptoms
Quality of life
Age
Gender
Education
Initial treatment
Nicotine dependence
Explaining LDA
Block 1
Depressive symptoms
Quality of life
Block 2
Depressive symptoms
Quality of life
Age
Gender
Education
Initial treatment
Nicotine dependence

.26

.14

1.39

.17

.08
.25
-.13
.03
-.14
.05
.04

.28
.15
.35
6.14
2.01
5.97
1.76

.39
1.24
.27
.16
-.81
.27
.18

.70
.23
.79
.88
.43
.79
.86

.04
-.07

.26
.15

.21
-.36

.84
.72

.14
-.03
-.06
.00
-.01
.10
.26

.28
.15
.35
6.14
2.01
5.97
1.76

.65
-.16
-.31
.02
-.08
.54
1.23

.52
.87
.76
.99
.94
.59
.23

-.12
-.16

.25
.14

-.65
-.86

.52
.40

-.06
-.19
-.06
.07
-.31
.38
-.12

.25
.14
.31
5.47
1.79
5.3
1.57

-.29
-1.03
-.30
.43
-1.98
2.33
-.65

.77
.31
.77
.67
.06
.03
.52

Note. *p < .05; **p < .01; ***p < .001. All outcome scores reported are change scores from
intake to Time 2. Standardized beta (β) coefficients and unstandardized standard error (SE)
coefficient values are reported. Final R2 and F statistics are reported for significant models.
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Table 7
Moderating Effects of Social Support on the Relationship between Violence and Time 1
Change in Cigarette Use
Predictor Variable

Beta

SE

t

p

Community violence
Block 1
Social support
Community violence

-.02
-.04

.07
.04

-.11
-.22

.91
.83

Block 2
Social support
Community violence
Age
Gender
Education
Initial treatment
Nicotine dependence
Block 3
Social support
Community violence
Age
Gender
Education
Initial treatment
Nicotine dependence
Soc. support by Comm. violence
Intimate partner violence
Block 1
Social support
Intimate partner violence
Block 2
Social support
Intimate partner violence
Age
Gender
Education
Initial treatment
Nicotine dependence
Block 3
Social support

-.02
-.06
.11
-.34
-.30
.22
.19

-.48
-1.02
.08
-.37
-.30
.25
.18
.96

-.04
-.37

-.01
-.09
.10
-.31
-.28
.19
.19

-.23

.04
.07
.10
1.87
.61
1.75
.50

.13
.42
.10
1.89
.61
1.77
.50
.00

.04
.06

.04
.07
.10
1.83
.67
1.81
.50

.06

-.13
-.34
.66
-2.15
-1.99
1.46
1.10

-1.00
-1.06
.46
-2.27
-1.98
1.60
1.04
1.01

-.27
-2.44

-.05
-.49
.60
-1.10
-1.67
1.23
1.11

-.95

R2 (F)

∆F

.01

.03

.34 (2.40)*

3.35*

.37 (2.23)*

1.03

.14 (2.10)

2.10

.35 (2.43)*

2.03

.90
.73
.52
.04
.06
.15
.28

.32
.30
.65
.03
.06
.12
.31
.32

.79
.02

.10
.62
.56
.04
.11
.23
.28

.35
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Intimate partner violence
Age
Gender
Education
Initial treatment
Nicotine dependence
Soc. support by Part. violence

-1.16
.11
-.32
-.27
.20
.17
1.10

.38
.10
1.82
.67
1.81
.50
.00

-1.24
.64
-2.08
-1.63
1.28
1.01
1.17

.22
.53
.04
.11
.21
.32
.25
.37 (2.32)*

1.36

Note. *p < .05; **p < .01; ***p < .001. All outcome scores reported are change scores from intake to
Time 1. Standardized beta (β) coefficients and unstandardized standard error (SE) coefficient values
are reported. R2, F, and F change statistics are reported.
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Table 8
Moderating Effects of Social Support on the Relationship between Depressive Symptoms and
Time 1 Change in Withdrawal
Predictor Variable

Beta

SE

t

p

Depressive Symptoms
Block 1
Social support
Depressive symptoms

-.05
.36

.10
.17

-.30
2.10

.77
.04

Block 2
Social support
Depressive symptoms
Age
Gender
Education
Initial treatment
Nicotine dependence
Block 3
Social support
Depressive symptoms
Age
Gender
Education
Initial treatment
Nicotine dependence
Soc. support by Dep. Symptoms

-.02
.43
-.09
.01
-.10
.05
.11

-.32
-.42
-.13
-.06
-.11
.05
.14
.77

.11
.19
.24
4.24
1.39
4.13
1.25

.21
.96
.25
4.58
1.40
4.15
1.27
.01

-.11
2.14
-.44
.02
-.59
.29
.55

-.81
-.42
-.64
-.30
-.68
.27
.68
.88

R2 (F)

∆F

.15 (3.28)*

3.28*

.17 (.95)

.17

.19 (.93)

.77

.92
.04
.66
.99
.56
.78
.59

.42
.68
.53
.76
.50
.79
.51
.39

Note. *p < .05; **p < .01; ***p < .001. All outcome scores reported are change scores from intake to
Time 1. Standardized beta (β) coefficients and unstandardized standard error (SE) coefficient values
are reported. R2, F, and F change statistics are reported.
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Table 9
Moderating Effects of Social Support on the Relationship between Depressive Symptoms/Life
Satisfaction and Time 1 Change in Cigarette Use
Predictor Variable

Beta

SE

t

p

Depressive Symptoms
Block 1
Social support
Depressive symptoms

-.01
.05

.05
.09

-.04
.29

.97
.78

Block 2
Social support
Depressive symptoms
Age
Gender
Education
Initial treatment
Nicotine dependence
Block 3
Social support
Depressive symptoms
Age
Gender
Education
Initial treatment
Nicotine dependence
Soc. support by Dep. Symptoms
Life satisfaction
Block 1
Social support
Life satisfaction
Block 2
Social support
Life satisfaction
Age
Gender
Education
Initial treatment
Nicotine dependence
Block 3
Social support

.08
.17
.06
-.33
-.33
.23
.25

-.16
-.51
.03
-.38
-.34
.23
.28

.04
-.13

.09
-.17
.07
-.34
-.33
.22
.21

.08

.04
.08
.10
1.77
.58
1.72
.52

.09
.40
.11
1.91
.59
1.74
.53

.05
.05

.05
.05
.10
1.78
.58
1.72
.50

.05

.45
.95
.36
-2.20
-2.30
1.53
1.41

-.48
-.59
.15
-2.33
-2.35
1.50
1.51

.19
-.64

.50
-.95
.44
-2.24
-2.29
1.45
1.26

.47

R2 (F)

∆F

.01 (.06)

.06

.36 (2.57)*

3.57*

.37 (2.31)*

.64

.01 (.22)

.22

.36 (2.57)*

3.48*

.66
.35
.72
.04
.03
.14
.17

.64
.56
.88
.03
.03
.14
.14

.85
.53

.62
.35
.66
.03
.03
.16
.22

.64
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Life satisfaction
Age
Gender
Education
Initial treatment
Nicotine dependence
Soc. support by Life satisfaction

.66
.04
-.38
-.35
.22
.24
-.85

.24
.10
1.84
.59
1.72
.50
.01

.75
.24
-2.40
-2.43
1.46
1.40
-.95

.46
.81
.02
.02
.16
.17
.35
.38 (2.36)*

.90

Note. *p < .05; **p < .01; ***p < .001. All outcome scores reported are change scores from intake to
Time 1. Standardized beta (β) coefficients and unstandardized standard error (SE) coefficient values
are reported. Final R2, F, and F change statistics are reported.
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Table 10
Moderating Effects of Social Support on the Relationship between Depressive Symptoms and
Time 2 Change in Withdrawal
Predictor Variable

Beta

SE

t

p

Depressive Symptoms
Block 1
Social support
Depressive symptoms

-.09
.34

.10
.18

-.54
1.97

.60
.04

Block 2
Social support
Depressive symptoms
Age
Gender
Education
Initial treatment
Nicotine dependence
Block 3
Social support
Depressive symptoms
Age
Gender
Education
Initial treatment
Nicotine dependence
Soc. support by Dep. Symptoms

-.01
.44
-.09
.07
-.10
-.09
.25

-.36
-.55
-.14
-.01
-.12
-.10
.29
.91

.11
.20
.25
4.41
1.44
4.29
1.30

.22
.99
.26
4.73
1.45
4.29
1.31
.01

-.07
2.28
-.47
.40
-.65
-.55
1.28

-.97
-.58
-.72
-.02
-.76
-.57
1.44
1.07

R2 (F)

∆F

.15 (3.32)*

3.32*

.22 (1.32)

.60

.25 (1.31)

1.14

.94
.03
.65
.69
.52
.59
.21

.34
.57
.48
.98
.46
.57
.16
.29

Note. *p < .05; **p < .01; ***p < .001. All outcome scores reported are change scores from intake to
Time 1. Standardized beta (β) coefficients and unstandardized standard error (SE) coefficient values
are reported. Final R2, F, and F change statistics are reported.

74
Table 11
Selected Item Endorsements of Community Violence Exposure on Things I Have Seen
and Heard

Item
Heard guns being shot

Prevalence (%)
At least once
Never
87.5

12.5

90

10

Seen drug deals

82.5

17.5

Seen somebody being beat up

82.5

17.5

Been beaten up

62.5

37.5

Seen somebody get stabbed

42.5

57.5

Seen somebody get shot

55

45

Seen a gun in my home (not my own gun)

35

65

Seen drugs/drug paraphernalia (items used to administer
drugs) in my neighborhood

85

15

Somebody threatened to kill me

30

70

Seen a dead body outside

45

55

Somebody threatened to shoot me

35

65

Somebody threatened to stab me

30

70

Seen somebody in my home get shot or stabbed

15

85

Seen somebody arrested

Note. One-hundred percent of participants reported at least one community violence event.
Above items represent selected items from the Things I Have Seen and Heard. Reverse-scored
items are not presented.
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Table 12
Selected Item Endorsements of Intimate Partner Violence Victimization on Revised
Conflict Tactics Scale

Item
My partner insulted or swore or shouted or yelled at me

Past-year Prevalence (%)
At least once
Never
57.5

42.5

20

80

17.5

82.5

15

85

My partner destroyed something belonging to me or threatened
to hit me

12.5

87.5

Went see a doctor (M.D.) or needed to see a doctor because of
a fight with my partner

10

90

My partner used force (like hitting, holding down, or using a
weapon) to make me have sex

10

90

Had a sprain, bruise, or small cut, or felt pain the next day
because of a fight with my partner
My partner pushed, shoved, or slapped me
My partner punched or kicked or beat me up

10
90
My partner insisted on sex when I did not want to or insisted on
sex without a condom (but did not use physical force)
Note. Sixty percent of participants reported at least one intimate partner violence victimization
event. Above items are violence victimization items from Revised Conflict Tactics Scale (Short
Form) presented in order of item severity.
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Table 13
Selected Item Endorsements of Intimate Partner Violence Perpetration on Revised
Conflict Tactics Scale

Item
I insulted or swore or shouted or yelled at my partner

Past-year Prevalence (%)
At least once
Never
65

35

17.5

82.5

I pushed, shoved, or slapped my partner

20

80

I punched or kicked or beat up my partner

10

90

I destroyed something belonging to my partner or threatened to
hit my partner

20

80

My partner went see a doctor (M.D.) or needed to see a doctor
because of a fight with me

10

90

12.5

87.5

My partner had a sprain, bruise, or small cut, or felt pain the
next day because of a fight with me

I used force (like hitting, holding down, or using a weapon) to
make my partner have sex

10
90
I insisted on sex when my partner did not want to, or insisted
on sex without a condom (but did not use physical force)
Note. Sixty-eight percent of participants reported at least one intimate partner violence
perpetration event. Above items are violence perpetration items from Revised Conflict Tactics
Scale (Short Form) presented in order of item severity.
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Table 14
Mean Reports of Life Satisfaction in 17 Areas of Life Functioning
Life Area
Standard of Living
Work
Health
Neighborhood
Civic Action
Community
Recreation
Creativity
Love Relationships
Home
Self-regard
Learning
Philosophy of Life
Relationships with Relatives
Social Service
Friendships
Relationships with Children
Total score

Mean
0.05
0.08
0.20
0.33
0.45
0.58
0.67
0.83
0.85
0.90
1.03
1.13
1.18
1.23
1.25
1.48
1.60
13.75

SD
1.10
1.99
1.76
1.85
1.95
1.77
1.88
1.85
2.06
1.85
1.69
1.61
1.52
1.75
1.66
1.72
1.50
21.61

Note. Items are from the Quality of Life Inventory, presented in ascending order of satisfaction
(i.e., lowest mean satisfaction scores to highest). Items are scored on a scale from -3 to 3, with
higher scores indicate greater life satisfaction.
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Figure 1
Reductions in Nicotine Withdrawal by High/Low Depression Scores

40
High Depression
Scores

Mean Withdrawal Score

35
30

33.4***

Low Depression
Scores

25
20

22.5**

22.6*

11

11.3

Post-Phase 1

Post-Phase 2

15
10
5

9

0
Intake

Time in Treatment
Note. Group means differed significantly at each time point at the following levels: *p < .05; **p <
.01; ***p < .001. Post-Phase 1 and Post-Phase 2 values represent raw values (not changescores) at each time point. Change score values at each time point also differed significantly
between high and low depression scorers.

79
REFERENCES
Ackerson, L.K., Kawachi, I., Barbeau, E.M., & Subramannian, S.V. (2007). Exposure to
domestic violence associated with adult smoking in India: A population-based
study. Tobacco Control, 12, 378-383.
Alessi, S.M., Petry, N.M., & Urso, J. (2008). Contingency management promotes
smoking reductions in residential substance abuse patients. Journal of Applied
Behavior Analysis, 41, 617-622.
American Psychological Association, (2007). Trauma and HIV/AIDS: A Summary of
Research Results. Washington, DC: Office of International Affairs, 2007.
Antelman, G., Kaaya, S., Wei, R., Mbwambo, J., Msamanga, G.I., Fawzi, W.W., Smith,
M.C. (2007). Depressive symptoms increase risk of HIV disease progression and
mortality among women in Tanzania. Journal of Acquired Immune Deficiency
Syndromes, 4, 470 –7.
Ashton, E., Vosvick, M., Chesney, M., Gore-Felton, C., Koopman, C., O’Shea, K.,
Maldonado, J., Bachmann, M.H., Israelski, D., Flamm, J., Spiegel, D. (2005).
Social support and maladaptive coping as predictors of change in physical health
symptoms among person living with HIV/AIDS. AIDS Patient care and STDs,
19(9), 587-598. doi: 10.1089/apc.2005.19.587.
Aubin, H. (2002). Tolerability and safety of sustained-release bupropion in the
management of smoking cessation. Drugs, 62(2), 45-52.
Barrera, M. (1986). Distinctions between social support concepts, measures, and
models. American Journal of Community Psychology, 14, 413–445.

80
Beck, A. T., Steer, R. A., & Brown, G. K. (1996). Manual for the Beck Depression
Inventory II. San Antonio, TX: Psychological Corporation.Brown, R., Lejuez, C.,
Kahler, C., Strong, D. (2002). Distress tolerance and duration of past smoking
cessation attempts. Journal of Abnormal Psychology, 111(1), 180-185.
Beckham, J.C., Feldman, M.E., Vrana, S.R., Mozley, S.L., Erkanli, A., Clancy, C.P., &
Rose, J.E. (2005). Immediate antecedents of cigarette smoking in smokers with and
without posttraumatic stress disorder: A preliminary study. Experimental and Clinical
Psychopharmacology, 13, 219-228.
Benowitz, N.L., Hukkanen, J., & Jacob, P. (2009). Nicotine chemistry, metabolism,
kinetics and biomarkers. Handbook of Experimental Pharmacology, 192, 29-60.
Biglino A, Limone P, Forno B, et al. (1995). Altered adrenocorticotropin and cortisol
response to corticotropin-releasing hormone in HIV-1 infection. European Journal
of Endocrinology, 133, 173-179.
Brady, S.S., Tschann, J.M., Pasch, L.A., Flores, E., & Ozer, E.J. (2009). Cognitive
coping moderates the association between violent victimization by peers and
substance use among adolescents. Journal of Pediatric Psychology, 34(3), 304310. Doi: 10.1093/jpepsy/jsno76
Brewer, J.A., Bowen, S., Smith, J.T., Marlatt, G.A., Potenza, M.N. (2010). Mindfulnessbased treatments for co-occuring depression and substance use disorders: What
can we learn from the brain? Addiction, 105(10), 1698-1706. doi: 10.1111/j.13600443.2009.02890.x.
Brown, R.A., Burgess, E.S., Sales, S.D., Whitely, J.A., Evans, D.M., & Miller, I.W.
(1998). Reliability and validity of a Smoking Timeline Follow-Back Interview.

81
Psychology of Addictive Behaviors, 12(2), 101-112. Doi: 10.1037/0893164X.12.2.101.
Buckner, J. C., Beardslee, W. R., & Bassuk, E. L. (2004). Exposure to violence and lowincome
children’s mental health: Direct, moderated, and mediated relations. American
Journal of Orthopsychiatry, 74, 413–423.
Burke, J.G., Thieman, L.K., Gielen, A.C., O’Campo, P., & McDonnell, K.A. (2005).
Intimate partner violence substance use, and HIV among low-income women.
Violence Against Women, 11(9), 1140-1161. doi: 10.1177/1077801205276943.
Burkhalter, J.E., Springer, C.M., Chhabra, R., Ostroff, J.S., & Rapkin, B.D. (2005).
Tobacco use and readiness to quit smoking in low-income HIV-infected persons.
Nicotine & Tobacco Research, 7, 511-522.
Calhoun, P.S., Dennis, M.F., & Beckham, J.C. (2007). Emotional reactivity to trauma
stimuli and duration of past smoking cessation attempts in smokers with
posttraumatic stress disorder. Experimental and Clinical Psychopharmacology,
15, 256-263.
Carlson, L., Goodey, E., Bennett, M.H., Taenzer, P., & Koopmans, J. (2002). The
addition of social support to a community-based large-group behavioral smoking
cessation intervention: Improved cessation rates and gender differences.
Addictive Behaviors, 27, 547-549.
Centers for Disease Control and Prevention (CDC). (2014, January 17). Current
cigarette smoking among adults – United States, 2005-2012. Morbidity and

82
Mortality Weekly Report, 63(2), 29-34. Retrieved from
http://www.cdc.gov/mmwr/pdf/wk/mm6302.pdf.
Centers for Disease Control and Prevention. Current cigarette smoking among adults—
United States, 2005-2014. Morbidity and Mortality Weekly Report, 64(44), 1233–
40.
Cinciripini P.M., Wetter, D.W., Fouladi, R.T., et al. (2003). The effects of depressed
mood on smoking cessation: mediation by postcessation self-efficacy. Journal of
Consulting & Clinical Psychology, 71, 292-301.
Clark, C., Ryan, L., Kawachi, I., Canner, M., Berkman, L., & Wright, R. (2007).
Witnessing community violence in residential neighborhoods: a mental health
hazard for urban women. Journal of Urban Health: Bulletin of the New York
Academy of Medicine, 85(1), 22-38.
Clark, H.J., Lindner, G., Armistea, L., & Austin, B.J. Stigma, disclosure, and
psychological functioning among HIV-infected and non-infected African-American
women. (2003). Women Health, 38(4), 57-71.
Cohen, J. (1998). Statistical power analysis for the behavioral sciences (2nd ed.)
Hillsdale, NJ: Lawrence Erlbaum Associates, Publishers.
Cohen, S., Hoberman, H. (1983). Positive events and social supports as buffers of life
change stress. Journal of Applied Social Psychology, 13(99-125).
Cohen, S., & Wills, T. (1985). Stress, social support, and the buffering hypothesis.
Psychological Bulletin, 98(2), 310-357. Cohen S, Lichtenstein E. (1990).
Perceived stress, quitting smoking, and smoking relapse. Health Psychology, 9,
466–478.

83
Collins, B.N., Wileyto, E.P., Patterson, F., Rukstalis, M., Audrain-McGovern, J.,
Kaufman, V., Pinto, A., Hawk, L., Niaura, R., Epstein, L.H., Lerman, C. (2003).
Gender differences in smoking cessation in a placebo-controlled trial of
bupropion with behavioral counseling. Nicotine & Tobacco Research, 6(1), 27-37.
Crane, C.A., Hawes, S.W., & Weinberger, A.H. (2013). Intimate partner violence
victimization and cigarette smoking: A meta-analytic review.Trauma, Violence, &
Abuse, 1-11. doi: 10.1177/1524838013495962.
Crothers, K., Griffith, T.A., McGinnis, K.A., Rodrighez-Barradas, M.C., Leaf, D.A.,
Weissman, S., Gibert, C.L., Butt, A.A., & Justice, A.C. (2005). The impact of
cigarette smoking on mortality, quality of life and comorbid illness among HIVpositive veterans. Journal of Internal Medicine, 20, 1142-1145.
Currier, M.B., Molina, G., & Kato, M. (2003). A prospective trial of sustained-release
bupropion for depression in HIV-seropositive and AIDS patients.
Psychosomatics, 44(2), 120-125. doi: 10.1176/appi.psy.44.2.120.
Dahlberg, L.L., & Krug, E.G. (2002). Violence: A global public health problem. In: Krug
E.G., Dahlberg, L.L., Mercy, J.A., Zwi, A.B., & Lozano, R. (eds). World Report on
Violence and Health. Geneva, Switzerland: World Health Organization: 1-56.
Delucchi, K., & Bostrom, A. (2004). Methods for analysis of skewed data distributions in
psychiatric clinical studies: working with many zero values. American Journal of
Psychiatry, 161, 1159-1168).
Derogatis, L. R. (1977). SCL-90-R (revised version) Manual I. Baltimore, MD: Johns
Hopkins University School of Medicine.

84
Derogatis, L. R., & Melisaratos, N. (1983). The Brief Symptom Inventory: An
introductory report. Psychological Medicine, 13, 595-605.
de Wit, H. (2009). Impulsivity as a determinant and consequence of drug use: a review
of underlying processes. Addiction Biology, 14(1), 22-31.
http://dx.doi.org/10.1111/j.1369-1600.2008.00129.x.
Dimeff, L.A. & Linehan, M.M. (2008). Dialectical behavior therapy for substance
abusers. Addiction Science and Clinical Practice, 4(2), 39-47.
Ellis, P.D. (2010). The essential guide to effect sizes (1st ed.). Cambridge University
Press: Cambridge, UK. ISBN 0521142466.
Faul, F., Erdfelder, E., Lang, A.G., & Buchner, A. (2007). GPower 3: A flexible statistical
power analysis program for the social, behavioral, and biomedical sciences.
Behavior Research Methods, 39, 175-191.
Feldman, J.G., Minkoff, H., Schneider, M.F., Gange, S.J., Cohen, M., Watts, H., Gandhi,
M., Mocharnuk, R.S., & Anastos, K. (2006). Association of cigarette smoking with
HIV prognosis among women int eh HAART era: A report from the women’s
interagency HIV study. American Journal of Public Health, 96, 1060-1065.
Feldner, M.T., Babson, K.A., & Zvolensky, M.J. (2007). Smoking, traumatic event
exposure, and post-traumatic stress: A critical review of the empirical
literature. Clinical Psychology Review, 27, 14-45.
Fiore, M.C., Jaen, C.R., Baker, T.B., Bailey, W.C., Benowit, S.J., Curry, S.F., Dorfman,
E.S., Froelicher, E.S., Goldstein, M.G., Healton, C.G., Henderson, P.N., &
Heyman, R.B., et al. (2008). Treating tobacco use and dependence: 2008
update. Rockville, MD: U.S. Department of Health and Human Services, Public
Health Service.

85
Fischer, P., Wicks, J., Shaffer, D., Piacentini, J., & Lapkin, J. (1992). Diagnostic
Interview
Schedule for Children Users' Manual. New York: Division of Child and Adolescent
Psychiatry, New York Psychiatric Institute.
Fischer, P., Shapiro, S., Breakey, W., Anthony, J., Kramer, M. (1986). Metal health and
social characteristics of the homeless: a survey of mission users. American
Journal of Public Health, 76(5), 519-524.
Ford, J., Hawke, J., Alessi, S., Ledgerwood, D., & Petry, N. (2007). Psychological
trauma and PTSD symptoms as predictors of substance dependence treatment
outcomes. Behavior Research and Therapy, 45, 2417-2431.
Foster, J.D., Kuperminc, G.P., & Price, A.W. (2004). Gender differences in posttrauatic
stress and related symptoms among inner-city minority youth exposed to
community violence. Journal of Youth and Adolescence, 33(1), 59-69.
Fowler, P., Tompsett, C., Braciszewski, J., Jacques-Tiura, A., Baltes, B. (2009).
Community violence: a meta-analysis on the effect of exposure and health
outcomes of children and adolescents. Development and Psychopathology, 21,
227-259.
Frisch, M.B. (1994). Manual and treatment guide for the Quality of Life Inventory.
Minneapolis, MN: National Computer Systems.
Frisch, M.B., Clark, M.P., Rouse, S.V., Rud, D., Paweleck, J.K., Greenstone, A., &
Kopplin, A. (2005). Predictive and treatment validity of life satisfaction and the
quality of life inventory. Assessment, 12(66), 66-78.

86
Frost, J. (2014, October, 16). How important are normal residuals in regression
analysis? Minitab, Inc. Retrieved from Minitab.com.
Gelman, A., & Hill, J. (2006). Data analysis using regression and multilevel/hierarchical
models. Cambridge, UK: Cambridge University Press. ISBN 9780521686891.
Gelman, A., Hill, J., & Yajima, Gelman, A., Hill, J., & Yajima, M. (2012). Why we
(usually) don't have to worry about multiple comparisons. Journal of Research on
Educational Effectiveness, 5, 189–211.
http://dx.doi.org/10.1080/19345747.2011.618213.
Gladstein, J., Rusonis, E. S. & Heald, F. P. (1992). A comparison of inner-city and
upper middle-class youths’ exposure to violence. Journal of Adolescent Health,
13, 275–280.
Golub, E.T., Astemborski, J.A., Hoover, D.R., Anthony, J.C., Vlahov, D., Strathdee, S.A.
(2003). Psychological distress and progression to AIDS in a cohort of injection
drug users. Journal of Acquired Immune Deficiency Syndrome, 32, 429 –34.
Gorman-Smith, D., Henry, D. B., & Tolan, P. H. (2004). Exposure to community violence
and violence perpetration: the protective effects of family functioning. Journal of
Clinical Child and Adolescent Psychology, 33, 439–449.
Gostin, L.O., & Webber, D.W. (1998). HIV infection and AIDS in the public health and
health care systems. The Journal of the American Medical Association, 279(14),
1108-1113. doi: 10.1001/jama.279.14.1108.
Hair, J.F., Anderson, R.E., Tatham, R.L., & Black, W.C. (1995). Multivariate data
analysis (4th ed.). Upper Saddle River, NJ, USA: Prentice-Hall, Inc. ISBN: 0-03349020-9.

87
Halcon, L. L., & Lifson, A. R. (2004). Prevalence and predictors of sexual risks among
homeless
youth. Journal of Youth and Adolescence, 33(1), 71–80.
Higgins, J., & Green, S. (editors). Cochrane handbook for systematic reviews of
interventions, Version 5.1.0, updated March, 2011. The Cochrane Collaboration,
2011. Available from www.cochrane-hadbook.org.
Higgins, S.T., Heil, S.H. Solomon, L.J., Bernstein, I.M., Lussieur, J.P., Abel, R.L., Lynch,
E., & Badger, G.J. (2004). A pilot study on voucher-based incentives to promote
abstinence from cigarette smoking during pregnancy and postpartum. Nicotine &
Tobacco Research, 6, 1015-1020.
Holmes, W.C., & Pace, J.L. (2002). HIV-seropositive individuals’ optimistic beliefs about
prognosis and relation to medication and safe sex adherence. Journal of General
Internal Medicine, 17(9), 677-683.
Humphrey, N. (2014). Posttraumatic Stress Disorder among people living with HIV/AIDS
[PDF document]. Retrieved from Albany Medical Center website:
http://www.amc.edu/Patient/services/HIV/edu_subpgs/documents/Humphrey_PT
SD_HIV_Mental_Health_Update.pdf
Hughes, J.R., Stead, L.F., Hartmann-Boyce, J., Cahill, K., & Lancaster, T. (2014).
Antidepressants for smoking cessation (review). The Cochrane Library, 1, 1-174.
Ironson, G., Balbin, E., Stuetzle, R., Fletcher, M., O’Cleirigh, C., Laurenceau, J.P.,
Schneiderman, N., & Solom, G. (2005). Dispositional optimism and the
mechanisms by which it predicts slower disease progression in HIV: Proactive

88
behavior, avoidant coping, and depression. International Journal of Behavioral
Medicine, 12(2), 86-97. doi: 10.1207/s15327558ijbm1202_6.
Ironson, G.H., & Hayward, H. Do positive psychosocial factors predict disease
progression in HIV-1? A review of the evidence. (2008). Psychosomatic
Medicine, 70(5), 546-554. Doi: 10.1097/PSY.0b013e318177216c.
Javors, M.A., Hatch, J.P., & Lamb, R.J. (2005). Cut-off levels for breath carbon
monoxide as a marker for cigarette smoking. Addiction, 100(2), 159-167.
Jun, H., Rich-Edwards, J.W., Boynton-Jarrett, R., & Wright, R.J. (2008). Intimate partner
violence and cigarette smoking: Association between smoking risk and
psychological abuse with and without co-occurrence of physical and sexual
abuse. American Journal of Public Health, 98(3), 527-535.
Kelly, B., Raphael, B., Judd, F., Kernutt, G., Burnett, P., Burrows, G. (1998).
Posttraumatic stress disorder in response to HIV infection. General Hospital
Psychiatry, 20, 345-352.
Kimberling, R. et al. (1999). Traumatic stress in HIV-infected women. AIDS Education
and Prevention, 11(4), 321-31.
Koenen, K.C., Hitsman, B., Lyons, M.J., Niaura, R., McCaffery, J., Goldberg, J. et al.
(2005). A twin registry study of the relationship between posttraumatic stress
disorder and nicotine dependence in men. Archives of General Psychiatry, 62,
1258–1265.
Kreek, M.J., Nielson, D.A., Butelman, E.R., & LaForge, K.S. (2005). Genetic influences
on impulsivity, risk-taking, stress responsivity and vulnerability to drug abuse and

89
addiction. Nature Neuroscience, 8(11), 1450-1457.
http://dx.doi.org/10.1038/nn1583.
La Gory, M., Fitzpatrick, K., & Ritchey, F. (2001). Life chances and choices: Assessing
quality of life among the homeless. The Sociological Quarterly, 42, 633–651.
Lai, D.T., Cahill, K., Qin, Y., & Tang, J.L. Motivational interviewing for smoking
cessation (review). (2010). The Cochrane Library, 3. doi:
10.1002/14651858.CD006936.pub2.
Ledgerwood, D.M., Alessi, S.M., Hanson, T., Godley, M., & Petry, N.M. (2008).
Contingency management for attendance to group substance abuse treatment
administered by clinicians in community clinics. Journal of Applied Behavior
Analysis, 41, 617-622.
Ledgerwood, D., Arfken, C., Petry, N., & Alessi, S. (2014). Prize contingency
management for smoking cessation: a randomized trial. Drug and Alcohol
Dependence, 133(2), 324-329. doi: 10.1016/j.drugalcdep.2013.06.015.
Leserman, J., Perkins, D.O., & Evan, D.L. (1992). Coping with the threat of AIDS: The
role of social support. American Journal of Psychiatry, 149(11), 1514-1520.
Leserman, J., Jackson, E.D., Petitto, J.M., Golden, R.N., Silva, S.G., Perkins, D.O., Cai,
J., Folds, J.D., Evans, D.L. (1999). Progression to AIDS: the effects of stress,
depressive symptoms, and social support. Psychosomatic Medicine, 61, 397–
406.
Leserman, J., Petitto, J.M., Gu, H., Gaynes, B.N., Barroso, J., Golden, R.N., Perkins,
D.O., Folds, J.D., Evans, D.L. (2002). Progression to AIDS, a clinical AIDS

90
condition, and mortality: psychosocial and physiological predictors. Psychological
Medicine, 32, 1059 –73.
Leventhal, A., Ameringer, K., Osborn, E., Zvolensky, M., & Langdon, K. (2013). Anxiety
and depressive symptoms and affective patterns of tobacco withdrawal. Drug
and Alcohol Dependence.
Leventhal, A., Greenberg, J., Trujillo, M., Ameringer, J., Lisha, N., Pang, R., &
Montterosso, J. (2013). Positive and negative affect as predictors of urge to
smoke: Temporal factors and meditational pathways. Psychology of Addictive
Behaviors, 27(1), 262-267.
Linehan, M.M., Dimeff, L.A., Reynolds, S.K., Comtois, K.A., Welch, S.S., Heagerty, P.,
Kivlahan, D.R. (2002). Dialectical behavior therapy versus comprehensive
validation therapy plus 12-step for the treatment of opioid dependent women
meeting criteria for borderline personality disorder. Drug and Alcohol
Dependence, 67, 13-26.
Lutgendorf, S.K., Antoni, M.H., Ironson, G., Kilmas, N., Kumar, M., Starr, K., McCabe,
P., Cleven, K., Fletcher, M.A., Schneiderman, N. (1997). Cognitive-behavioral
stress management decreases dysphoric mood and herpes simplex virus-type 2
antibody titers in symptomatic HIV-seropositive gay men. Journal of Consulting
and Clinical Psychology, 65(1), 31-43. http://dx.doi.org/10.1037/0022006X.65.1.31.
Machtinger, E. L; Wilson, T. C; Haberer, J. E; Weiss, D. S. (2012). Recent trauma is
associated with antiretroviral failure and HIV transmission risk behavior among

91
HIV-positive women and female-identified transgenders. AIDS and Behavior,
16(8).
Maman, S., Mbwambo, J.K., Hogan, N.M., Kilonzo, G.P., Campbell, J.C., Weiss, E., &
Sweat, M.D. (2002). HIV-positive women report more lifetime partner violence:
Findings from a voluntary counseling and testing clinic in Dar es Salaam,
Tanzania. American Journal of Public Health, 92(8).
Martin, E.M., Pitrak, D.L., Weddington, W., Rains, N.A., Nunnally, G., Nixon, H.,
Grbesic, S., Vassileva, J., & Bechara, A. (2004). Cognitive impulsivity and HIV
serostatus in substance dependent males. Journal of the International
Neuropsychological Society, 10, 931-938. doi: 10.10170S1355617704107054.
Maulik, P.K.,Eaton, W.W., Bradshaw, C.P. (2010). The effect of social networks and
social support on common mental disorders following specific life events. Acta
Psychiatrica Scandivanica, 122, 118-128.
McFarlane, A., Bellissimo, A., & Norman, G. (1995). The role of family and peers in
social self-efficacy: Links to depression in adolescence. American Journal of
Orthopsychiatry 65:402–410.
McKee, S.A., O’Malley, S.S., Salovey, P., Krishnan-Sarin, S., & Mazure, C.M. (2005).
Perceived risks and benefits of smoking cessation: Gender-specific predictors of
motivation and treatment outcome. Addictive Behaviors, 30, 423-435. doi:
10.1016/j.addbeh.2004.05.027.
Mdodo, R., Frazier, E.L., Dube, S.R., Mattson, C.L., Sutton, M.Y., Brooks, J.T., &
Skarbinski, J. (2015). Cigarette smoking prevalence among adults with HIV

92
compared with the general adult population in the United States. Annals of
Internal Medicine, 162(5). doi: 10.7326/M14-0954.
Miller, G.E., & Cole, S.W. (1998). Social relationships and the progression of human
immunodeficiency virus infection: A review of evidence and possible underlying
mechanisms. Annals of Behavioral Medicine, 20(3), 181-189.
Morissette, S.B., Tull, M.T., Gulliver, S.B., Kamholz, B.W., & Zimering, R.T. (2007).
Anxiety, anxiety disorders, tobacco use, and nicotine: A critical review of
interrelationships.Psychological Bulletin, 133, 245-272.
Mrug, S., Windle, M. (2009). Bidirectional influences of violence exposure and
adjustment in early adolescence: externalizing behaviors and school
connectedness. Journal of Abnormal Child Psychology, 37, 611-623.
Muller, R., Goebel-Fabbri, A., Diamond, T., & Dinklage, D. (2000). Social support and
the relationship between family and community violence exposure and
psychopathology among high risk adolescents. Journal of Child Abuse and
Neglect, 24(4), 449-464.
Nordentoft, M. (2010). Crucial elements in suicide prevention strategies. Progress in
Neuro-Psychopharmacology & Biological Psychiatry, 35, 848-853.
Op Den Velde, W., Aarts, P.G., Falger, P.R., Hovens, J.E., Van Duijn, H., De Groen,
J.H., & Van Duijn, M.A. (2002). Alcohol use, cigarette consumption and chronic
post-traumatic stress disorder. Alcohol and Alcoholism, 37(4), 355-361.
Overstreet, S., & Braun, S. (2000). Exposure to community violence and post-traumatic
stress symptoms: mediating factors. American Journal of Orthopsychiatry, 70(2),
263-271.

93
Patterson, T.L., Shaw, W.S., Semple, S.J., Cherner, M., McCutchan, J.A., Atkinson,
J.H., Grant, I., & Nannis, E. (1996). Relationship of psychosocial factors to HIV
disease progression. Annals of Behavioral Medicine, 18(30). doi:
10.1007/BF02903937.
Paxton, K., Robinson, W., Shah, S., & Schoeny, M. (2004). Psychological distress for
African-American adolescent males: exposure to community violence and social
support as factors. Child Psychiatry and Human Development, 34(4), 281-296.
Pedrol-Clotet, E., Deig-Comerma, E., Ribell-Bachs, M., Vidal-Castell, I., GarciaRodriguez, P., & Soler, A. (2006). Bupropion use for smoking cessation in HIVinfected patients receiving antiretroviral therapy. Enfermedades Infecciosas y
Microbiologia Clinica, 24(8), 509-511. doi: 10.1157/13092468.
Perala, J., Suvisaari, J., Saarni, S., Kuoppasalmi, K., Isometsa, E., Pirkola, S.,
Partonen, T., Tuulio-Henriksson, A., Hintikka, J., Kieseppa, T., Harkanen, T.,
Koskinen, S., Lonngvist, J. (2007). Lifetime Prevalence of Psychotic and Bipolar I
Disorders in a General Population. Archives of General Psychiatry, 64(1), 19-28.
doi: 10.1001/archpsyc.64.1.19.
Perkins, K.A., Lerman, C., Coddington, S.B., Jetton, C., Kareltiz, J.L., Scott, J.A., &
Wilson, A.S. (2008). Initial nicotine sensitivity in humans as a function of
impulsivity. Psychopharmacology, 200, 529-544. doi: 10.1007/s00213-008-12317.
Peirce, J.M., Petry, N.M., Stitzer, M.L., Blaine, J., Kellogg, S., Satterfield, F., Schwartz,
M., Krasnansky, J., Pencer, E., Silva-Vazquez, L., Kirby, K.C., Royer-Malvestuto,
C., Roll, J.M., Cohen, A., Copersino, M., Kolodner, K., & Li, R. (2006). Lower-

94
cost incentives increase stimulant abstinence in methadone maintenance
treatment: A National Drug Abuse Treatment Clinical Trials Network study.
Archives of General Psychiatry, 63, 201-208.
Petry, N.M. (2000). A comprehensive guide to the application of contingency
management procedures in clinical settings. Drug and Alcohol Dependence,
58(1-2), 9-25.
Petry, N.M., Martin, B., Cooney, J.L., & Kranzler, H.R. (2000). Give them prizes and
they will come: Contingency management for treatment of alcohol dependence.
Journal of Consulting and Clinical Psychology, 68, 250-257.
Petry, N.M., Tedford, J., Austin, M., Nich, C., Carroll, K.M., & Rounsaville, B.J. (2004).
Prize reinforcement contingency management for treating cocaine users: how
long can we go and with whom? Addiction, 99(3), 349-360.
Petry, N.M., Alessi, S.M., Tedford, J., Austin, M., & Tardiff, M. (2005). Vouchers versus
prizes: Contingency management for treatment of substance abusers in
community settings. Journal of Consulting and Clinical Psychology, 73, 10051014.
Petry, N.M., Martin, B., & Simcic, F. (2005). Prize reinforcement contingency
management for cocaine dependence: Integration with group therapy in a
methadone clinic. Journal of Consulting and Clinical Psychology, 73, 354-359.
Petry, N.M., Alessi, S.M., & Ledgerwood, D.M. (2012). A randomized trial of
contingency management delivered by community therapists. Journal of
Consulting and Clinical Psychology, 80(2), 286-298. doi: 10.1037/a0026823.

95
Reid, R.J., Bonomi, A.E., Rivara, F.P., Anderson, M.L., Fishman, P.A., Carrell, D.S., &
Thompson, R.S. (2008). Intimate partner violence among men prevalence,
chronicity, and health effects. American Journal of Preventive Medicine, 34(6),
478-485. doi: 10.1016/j.amepre.2008.01.029.
Reid, H.H., Ledgerwood, D.M. (2015). High depression affects changes in nicotine
withdrawal and smoking urges throughout smoking cessation treatment:
Preliminary results. Addiction Research & Theory, 1-6. doi:
10.3109/16066359.2015.1060967.
Robinson, S.M., Sobell, L.C., Sobell, M.B., & Leo, G.I. (2012). Reliability of the Timeline
Followback for Cocaine, Cannabis, and Cigarette Use. Psychology of Addictive
Behaviors, 28(1), 154-162. doi: 10.1037/a0030992.
Sayles, J.N., Ryan, G.W., Silver, J.S., Sarkisian, C.A., & Cunningham, W.E. (2007).
Experiences of social stigma and implications for healthcare among a diverse
population of HIV positive adults. Journal of Urban Health: Bulletin of the New
York Academy of Medicine, 84(6). Doi: 10.1007/s11524-007-9220-4.
Scharf, D., & Shiffma, S. (2004). Are there gender differences in smoking cessation,
with and without bupropion? Pooled- and meta-analyses of clinical trials of
Bupropion SR. Addiction, 99, 1462-1469. doi: 10.1111/j.13600443.2004.00845.x.
Silverman, K., Wong, C.J., Umbricht-Schneiter, A., Montoya, I.D., Schuster, C.R., &
Preston, K.L. (1998). Broad beneficial effects of cocaine abstinence
reinforcement among methadone patients. Journal of Consulting and Clinical
Psychology, 68, 811-824.

96
Simoni, J.M., Pantalone, D.W., Plumer, M.D., & Huang, B. (2007). A randomized
controlled trial of a peer support intervention targeting antiretroviral medication
adherence and depressive symptomatology in HIV-positive men and women.
Health Psychology, 26(4), 488-495. doi: 10.1037/0278-6133.26.4.488.
Smith, P.H., Murray, C.E., & Coker, A.L. (2010). The coping window: A contextual
understanding of the methods women use to cope with battering. Violence and
Victims, 25. doi: 10.1891/0886-6708.25.1.18.
Theunick, A. et al (2010). HIV-related posttraumatic stress disorder: Investigating
traumatic events. AIDS Patient care and STDS, 24(8): 485-491.
Thoits, P. (2011). Problems linking social ties and support to physical and mental
health. Journal of Health and Social Behavior, 52, 145-163.
Thorndike, F.P., Wernicke, R., Pearlman, M.Y., & Haaga, A.F. (2006). Nicotine
dependence, PTSD symptoms, and depression proneness among male and
female smokers. Addictive Behaviors, 31(2), 223-231.
van belle, G. (2008). Statistical rules of thumb (2nd ed.). 2008. Hoboken, NJ: John Wiley
& Sons, Inc. ISBN 0470144483.
Verdejo-Garcia, A., Lawrence, A.J., & Clark, L. Impulsivity as a vulnerability marker for
substance-use disorders: Review of findings from high-risk research, problem
gamblers, and genetic association studies. Neuroscience and Behavioral
Reviews, 32, 777-810. doi:10.1016/j.neubiorev.2007.11.003.
Vidrine, D.J., Arduino, R.C.., & Gritz, E.R. (2007). The effects of smoking abstinence on
symptom burden and quality of life among persons living with HIV/AIDS. AIDS
Patient care, 21, 659-666.

97
Wagner, G.J., Bogart, L.M., Galvan, F.H., Banks, D., Klein, D.J. (2012). Discrimination
as a key mediator of the relationship between posttraumatic stress and HIV
treatment adherence among African American men. Journal of Behavioral
Medicine, 35(1), 8-18.
Weinberger, A., McKee, S., & George, T. (2012). Smoking cue reactivity in adult
smokers with and without depression: A pilot study. American Journal on
Addictions, 21(2), 136-144.
West S.G., Aiken, L.S. Toward understanding individual effects in multiple component
prevention programs: Design and analysis strategies. In: Bryant K, Windle M,
West S, editors. The science of prevention: Methodological advances from
alcohol and substance abuse research. Washington, DC: American
Psychological Association; 1997. pp. 167–209.
Wetter, D.W., Kenford, S.L., Smith, S.S., Fiore, M.C., Jorenby, D.E., & Baker, T.B.
(1999). Gender differences in smoking cessation. Journal of Consulting and
Clinical Psychology, 67(4), 555-562.
World Health Organization (WHO). (2002). World report on violence and health.
Geneva, World Health Organization. Retrieved from
http://whqlibdoc.who.int/publications/2002/9241545615_eng.pdf?ua=1.
World Health Organization (WHO). (2007). Gender and tobacco control: A policy brief.
Geneva, World Health Organization. ISBN 9789241595773.
Ziedonis, D., Hitsman, B., Beckham, J., Zvolensky, M., Adler, L., Audrain-McGovern, J.,
… Riley, W. (2008). Tobacco use and cessation in psychiatric disorders: National

98
Institute of Mental Health report. Nicotine & Tobacco Research, 10(12), 18111812.
Zuckerman, M., & Kuhlman, D.M. (2001). Personality and risk-taking: common biosocial
factors. Journal of Personality, 68(6), 999-1029. http://dx.doi.org/10.1111/14676494.00124.

99
ABSTRACT
THE MODERATING EFFECTS OF PROTECTIVE AND RISK FACTORS ON
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The rate of cigarette smoking is three-fold higher among adults living with Human
Immunodeficiency Virus (HIV)/Autoimmune Deficiency Syndrome (AIDS) than in the
general population (Centers for Disease Control and Prevention, 2015). Relative to nonsmoking HIV-positive adults, HIV-positive cigarette smokers have even higher mortality
rates, more physical health problems, greater tobacco-related health disparities, lower
quality of life, and more barriers to treatment. These barriers are often interrelated with
the significantly higher rate of trauma and violence exposure reported in both cigarette
smokers and persons living with HIV/AIDS (PLWHA; CDC). Violence exposure not only
predicts emotional distress and substance use, but also mediates between victimization
and cigarette use (e.g., Feldner, Babson, & Zvolensky, 2007). Psychological and
physical trauma additionally impact both short and long-term substance use treatment
outcomes, independent of treatment modality (e.g., Ford et al., 2007). Though social
support is consistently linked to both smoking behaviors, and mental and behavioral
outcomes for PLWHA, few studies have examined the role of social support in smoking
treatment among this population. Additionally, no studies have explored social and
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individual-level protective and risk factors in the context of a contingency management
smoking cessation treatment design. The aim of this study was to examine how different
risk and protective factors affect cessation outcomes among PLWHA undergoing
contingency-based treatment for cigarette smoking. Specifically, this study explored
how different components of violence (community and interpersonal partner violence),
distress, life satisfaction, and social support affect cigarette use and cessation success.
Study findings showed that intimate partner violence predicted increased initial change
in cigarette use, while community violence predicted reduced initial motivations for
quitting smoking. Increased depression scores predicted both initial and total treatment
change in withdrawal experience. Findings have implications for the assessment of and
therapeutic approaches to smoking cessation for smokers living with HIV/AIDS.

101
AUTOBIOGRAPHICAL STATEMENT
Holly Hannah Reid
EDUCATION AND TRAINING
Post-doctoral Fellowship in Addictions Psychology
John D. Dingell VA Medical Center, Detroit, MI

2016 – 2017

Pre-doctoral Internship in Clinical Psychology
Yale University, Department of Psychiatry, New Haven, CT
Primary Program: Forensic Addiction Services
Secondary Program: Adult Community Mental Health Services

2016

Ph.D. Clinical Psychology, Community Specialization
Wayne State University, Detroit, MI
Dissertation: The Moderating Effects of Protective and Risk Factors on
Outcomes for Behavioral Smoking Cessation Treatment among People
Living with HIV/AIDS

2016

M.A. Clinical Psychology
Wayne State University, Detroit, MI
Thesis: Community Violence, Psychological Distress, and Substance Use
in Emerging Adulthood: The Moderating Effects of Social Support

2012

B.A. Psychology, Anthropology minor
Washington University in St. Louis, St. Louis, MO

2010

Non-degree student
Yonsei University, Seoul, South Korea

2007

SELECTED PUBLICATIONS
Reid, H.H., & Baranoski, M.V. (2016). Expertise in determining service connection for mental
illness as cause of death. Journal of the American Academy of Psychiatry and the Law.
Toro, P.A., & Reid, H.H. (2016). Homelessness and mental health: A research perspective.
In H.S. Friedman (Ed.), Encyclopedia of Mental Health (2nd ed). Waltham, MA: Academic
Press, 325-331. doi:10.1016/B978-0-12-397045-9.00241-X
Reid, H.H., & Ledgerwood, D.M. (2015). High depression affects changes in nicotine
withdrawal and smoking urges throughout smoking cessation treatment: Preliminary results.
Addiction Research & Theory, 1-6. doi:10.3109/16066359.2015.1060967
PROFESSIONAL MEMBERSHIP
Society of Addiction Psychology (APA Div. 50)
Society for Community Research and Action (APA Div. 27)
American Psychological Association of Graduate Students
American Psychological Association

2013 – present
2011 – present
2011 – present
2011 – present

